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Abstract
Crystal Structure Investigations of Small Heat Shock
Proteins and Serine Palmitoyltransferase
Ian R. Williamson
The content of this thesis concerns the pursuit of protein structures from cradle
to grave. This process is illustrated though the progress made on two separate
proteins. The first is the serine palmitoyltransferase from Toxoplasma gondii
(TgSPT). This protein is of interest as sphingolipid biosynthesis in apicomplexan
parasites is currently the subject of study as a possible drug target, most no-
tably in Plasmodium. We begin by looking at the techniques of bioinformatics
used to analyse the amino acid sequence of this protein, and by calculation and
comparison with other known protein sequences we are able to begin to identify
the different domains of the protein and also to begin to identify their respective
functions. Bioinformatic techniques are then further used in order to design con-
structs to be moved forward for overproduction in vivo. A number of different
constructs showing significant soluble expression of various truncations of TgSPT
are reported, and various techniques relating to overexpression an purification are
considered, including high-throughput screening work undertaken at the Oxford
Protein Production Facility. The second protein looked at is the small heat shock
protein from Methanococcus jannaschii (MjHSP). This protein is used as a more
tractable analogue for the human α-B-crystallin. We look here at the wild type
protein as well as a mutant mimicking the disease-causing R120G mutation in
α-B-crystallin, R107G, and also two different truncation mutants, mimicking the
Q151X truncation. The processes relating to crystal growth and optimisation, to
data collection, and to data analysis and structure solution are then considered.
Finally, a redetermined structure of wild type MjHSP at significantly increased
resolution, and the structure of the R107G mutant are reported.
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1 The Importance of Structures
Perhaps the most ubiquitous functional unit across all the various forms of life
known to science is the protein. A protein is a biological macromolecule made up
of one or more chains of amino amino acids, connected and folded in particular
ways, giving the protein a unique form and function. The form and function
are themselves linked very closely, and a small change in form can create a very
significant change in function. Indeed it is in pursuit of a better understanding of
the function of these proteins that we seek to gain insight into the details of their
structure.
The structure can be broken down into a number of different levels of infor-
mation. The primary structure, the sequence of amino acids which make up the
protein, may be readily extracted from the sequence of DNA which codes for the
protein. It is at this level that the smallest changes can have the largest effect.
The mutation of one residue out of a thousand may render an active site unable
to perform its function, or indeed completely disrupt the higher folding of the
protein, again disrupting or even removing its function entirely. Many human
diseases can be traced back to the substitution or deletion of one or two amino
acids; a change in the primary structure. The secondary structure, the patterns
of folds associated with particular bonding motifs between acids, such as α-helices
and β-strands, may be to some extent inferred by well known rules of hydrogen
bonding motifs and the like. To this end there exist many computer programs
dedicated solely to the prediction of secondary structure, working only from the
primary structure and prior knowledge of the patterns of acids indicative of bond-
ing motifs. The tertiary structure, the relationship between these substructural
elements, may be inferred, to a lesser extent, by analogy with proteins of similar
sequence for which the structure has already been determined. The quaternary
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structure, the relationship between multiple protein units or chains, is more diffi-
cult to access, though may be inferred from behaviour in certain size dependent
methods.
One technique of great value in determining the secondary, tertiary, and in
some cases quartenary structure of proteins, is X-ray crystallography, and it is
this technique that is the main focus of the work to be outlined in the coming
chapters. A high resolution crystal structure can give deep insight into the details
of these levels of structure for the very simple reason that its end goal is a three
dimensional structural model of the protein, giving the location of each amino
acid, and in some cases each atom, in the protein. This is however a simplified
understanding of the technique, and there are many caveats to be applied, which
will be discussed in later chapters.
Figure 1: The structure of influenza A N9 neuraminidase (PDB Code: 1NNA)
and its inhibitor zanamivir. In the cartoon depiction of the protein α-helix is
shown in red; β-sheet in yellow; and random coil in green.
One prominent example where the complete understanding of a protein from
primary to quaternary structure played the key role in developing new treat-
ments for human diseases is the N9 neuraminidase from influenza A [1]. Figure 1
shows its X-ray crystal structure, solved to 2.5A˚ resolution, and the antiviral drug
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zanamivir. Neuraminidase is a surface antigen which accounts for 5-10% of the
total viral protein and plays a pivotal role in the viral life cycle [2]. Zanamivir was
designed as a transition state analogue by rational computer-aided drug design on
a basis of the structure of neuraminidase and has proven to be a potent inhibitor,
now widely used [3]. Such an example demonstrates quite clearly the use of de-
tailed structural information, and is often the target of a study, but beyond this
there are few aspects of a protein’s biology which cannot be better understood
with full structural information.
Figure 2: The growth of the total number of structures deposited in the Protein
Databank up to the end of 2011, as well as the number which were solved by
X-ray crystallography and NMR. EM contributes only 0.5% to the total number
of structures. Statistics taken from [4]
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1.1 X-Ray Crystallography
X-rays were first observed by Wilhelm C. Ro¨ntgen in 1895 [5] who produced the
first X-ray image, a picture of his wife’s hand. It was Max von Laue who proposed
that their wavelength (c.∼1A˚)2 may be of a similar magnitude to the atomic spac-
ing in crystals, and as such first demonstrated their diffraction [6]. Two years later
William L. Bragg published the first 3D atomic X-ray crystal structure, that of
sodium chloride [7]. Over the following decades, the understanding of the effects
involved and the development of modern technologies have driven the science for-
ward. Single crystal X-ray structure determination was first successfully applied
to a biological macromolecule by Sir John Kendrew who solved the structure of
sperm whale myoglobin in 1958 [8]. There are now nearly 80,000 protein crys-
tal structures recorded in the protein data bank (PDB) (Figure 2), and nearly
600,000 small molecule structures in the Cambridge Structural Database [9]. In-
deed protein crystallography has become such a widely used technique that the
number of structures in the PDB is now growing exponentially year on year, and
with continued investment in large-scale central facilities such as the Diamond
Light Source in Oxfordshire, this trend will only continue over the coming years.
1.2 The Serine Palmitoyltransferase from Toxoplasma gondii
The work described in this thesis concerns the pursuit of the structures, and the
relationship between the structure and function of two separate proteins. The
first of these is the Serine Palmitoyltransferase (SPT) from Toxoplasma gondii.
T. gondii is an organism of interest both in itself as a human pathogen of some
significance, and more importantly as a more tractable analogue of Plasmodium,
the causative agent of the disease malaria.
21 A˚ = 1× 10−10 m. By convention, the a˚ngstro¨m is the unit of distance used in crystallog-
raphy due to its convenient order of magnitude relative to the length of a chemical bond.
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Our work considers the pathway for sphingolipid biosynthesis as a possible target
drugs, and our previous work has shown that inhibition of this pathway causes
cell mortality in vivo [10]. Within this pathway, this project focuses on the SPT
as a key target enzyme in this chain. The main focus of the work on the SPT
is in the early stages of structure determination. Various truncates are designed
using bioinformatic techniques, and targeted with the aim of isolating significant
quantities of pure, monodisperse protein, which if successfully produced may then
be taken forward to crystallisation trials. Beyond this, the project aims to produce
crystals, from which the structure may be determined, and eventually used to
develop novel inhibitors.
1.3 Heat Shock Protein 16.5 from Methanococcus jannaschii
The second of the proteins considered is the Heat Shock Protein 16.5 from Methanococ-
cus jannaschii. This is again used as an analogue more suitable for laboratory
studies, in this case for human αB-crystallin. Human αB-crystallin is itself of in-
terest due to its role in human disease, most particularly myopathy and cataracts.
A number of mutations have been identified in human αB-crystallin which have
been shown to have a role in causing these conditions, and it is particularly the
analogues of these in Heat Shock Protein 16.5 that we will look into.
This part of the work begins with purified protein, which has been isolated
by colleagues in Durham University’s Department of Biological and Biomedical
Sciences, and therefore focuses on the work of crystallisation, diffraction and struc-
ture solution. Both the native protein and three mutants, two truncation mutants
and one point mutation, are studied. The end goal is to identify what effect the
mutations have on the structure, to identify how this shapes their role in human
disease, and whether potentially any drug might be developed to mitigate their
effect.
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2 Sphingolipid Biosynthesis in Toxoplasma gondii
as a Drug Target
2.1 Toxoplasma gondii and Toxoplasmosis
Toxoplasma gondii is an apicomplexan parasite closely related to species such
as Cryptosporidium and the causative agent of malaria, Plasmodium [11]. Due
to its tractability in the laboratory T. gondii is widely regarded as the model
system for the study of such parasites and is therefore well understood. T. gondii
infection affects a significant proportion of the world’s population; it is estimated
that 16–40% of people in the UK and USA and 50–80% of people in continental
Europe are infected [12]. In general no significant problem arises due to infection,
however, if a mother becomes infected for the first time during pregnancy the fetus
is at significant risk of retinochoroiditis, hydrocephalus, convulsions and cerebral
calcification [13]. In the least severe cases eyesight is impaired, the most severe
cases lead to death. The socioeconomic impact of toxoplasmosis is most apparent
in terms of the significant costs incurred in caring for children suffering from
mental retardation and blindness [14]. Further risks exist to transplant patients
treated with immunosuppressive agents and toxoplasmosis is one of the highest
causes of death in patients with AIDS with up to 30% of patients in Europe dying
from toxoplasmosis [15].
T. gondii has a complicated life cycle, with many stages. Indeed it may only
reproduce sexually in cats or other Felidæ. Cat fæces infected with oocysts may
then contaminate food and drink passing the infection on to humans directly or via
undercooked meat from an animal infected with T. gondii. The largest outbreak
in humans recorded was linked to a contaminated municipal water reservoir in
British Columbia, Canada [16]. Infection via food may be effectively prevented
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by a combination of thorough food preparation hygiene and either heating meat
to 67 [17], cooling it to -13 [18] or by gamma irradiation [19]. While current
therapies exist, they are generally based on a cocktail of drugs and evidence
of limited tolerance in individual cases and rising antibiotic resistance call for
renewed efforts in drug development.
2.2 Sphingolipids
Figure 3: The sphingolipid sphingomyelin. Three main parts may be identified:
sphingosine (the bottom long chain), phosphocholine (the right hand group) and
a fatty acid (the top long chain).
Sphingolipids are key components of all membranes. They are a class of lipids
made up of the aliphatic amino alcohol sphingosine and a fatty acid, for instance
sphingosine (figure 3). They were first noted as part of the array of molecules
present in cells by J. L. W. Thudicum who noted their presence in the brain in
1884 [20] and were first successfully characterised, gaining their current name, in
the middle of the last century [21]. It is now recognised that this class of amino
alcohols numbers in the hundreds, with significant variety in all aspects of their
chemistry [22]. Their roles in the cell are widespread, including the formation of
membrane lipid rafts particularly for cell signalling [23, 24] and recognition [25].
Significant study has been undertaken on the various enzymes involved in this
process [26], and recent work has identified sphingolipid biosynthesis as a possible
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drug target in apicomplexan parasite species due to the significant differences
between the synthetic pathways of animals and other species [10].
2.3 Serine Palmitoyltransferase
Serine palmitoyltransferase (SPT) is an enzyme involved in the early stages of sph-
ingolipid biosynthesis [27, 28]. It catalyses the Claisen condensation of L-serine
with palmitoyl CoA, both basic cellular metabolites, to form ketodihydrosph-
ingosine (KDS), the ‘long chain base’ of sphingolipids [29]. It belongs to the
α-oxoamine synthase (AOS) family of enzymes which catalyse condensation reac-
tions between a specific amino acid and an acyl CoA thioester substrate. These
enzymes fall into the larger category of fold type I pyridoxal-5’-phosphate (PLP)
dependent enzymes [30]. The structures for a number of enzymes from the AOS
family have been solved including 8-amino-7-oxononanoate synthase from E. coli,
which is involved in biotin synthesis [31, 32], 5-aminolevulinate synthase from
Rhodobacter capsulatus involved in tetrapyrrole metabolism [33, 34], 2-amino-3-
ketobutyrate CoA ligase from E. coli which is involved in threonine biosynthe-
sis [35] as well as the structure of the SPT from Sphingomonas paucimobilis [36].
After SPT, the KDS is reduced to sphinganine by 3-ketosphinganine reductase,
which is in turn acylated by dihydroceramide synthase to produce dihydroce-
ramide. This is then again reduced to ceramide by dihydroceramide reductase.
This is then transported to the Golgi apparatus where it is further metabolised
by sphingolipid synthase, producing phosphosingolipid. In this process, SPT has
been identified as the rate determining enzyme [27, 28], and it is this, combined
with its early place in the chain of sphingolipid biosynthesis that underpins our
interest in the enzyme.
The exact details of the quaternary structure of the T. gondii serine palmitoyl-
transferase (TgSPT) are currently unclear. We have identified two proteins likely
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Figure 4: Serine plamitoyltransferase catalyses the Claisen condensation of L-
serine with palmitoyl-CoA to form ketodihydrosphingosine.
to be involved in the condensation reaction shown in figure 4, though current anal-
yses suggest that only one, the subject of the current study, contains all of the
necessary active site residues, and is therefore likely to be fully active [37, 38]. It is
hoped that more detailed structural information will further elucidate this matter.
In yeast the analogous ‘long chain base synthase’ enzymes have a very complicated
topology with a number of transmembrane domains and at least three different
enzymes having been implicated in the condensation reaction [39, 40]. In the bac-
terium S. paucimobilis the enzyme is active as a water-soluble homodimer [41], the
crystal structure of which has been solved [36] (see section 2.3.3). Ikushiro has also
identified further bacterial analogues (from Sphingobacterium multivorum, Sphin-
gobacterium spiritivorum, and Bdellovibrio stolpii) that have also been shown to
exist as water-soluble homodimers [42]. Other work has gone into the identifica-
tion and characterisation of the mammalian analogue to these enzymes, which is
thought to exist as a heterodimer, though the exact functional relationship and a
lack of structural information makes comparison difficult [43, 44].
2.3.1 Pyridoxal-5’-phosphate Binding
A significant number of enzymes use internally bound PLP (shown in 5) as a co-
factor in their activity [45]; 4% of enzyme-catalysed reactions catalogued by the
Enzyme Commission are PLP dependent [46]. PLP is a phosphorylated derivative
of vitamin B6 [47, 48], the main function of which seems to be the stabilisation
9
Figure 5: An active vitamer of B6: Pyridoxal-5’-phosphate.
of anions created during reactions by the delocalisation of the negative charge
in the cofactor’s pi system. The mode of binding is as an internal aldimine with
the nitrogen atom in the side chain of a particular lysine residue in the struc-
ture [30, 49]. In the process of the reaction this internal aldimine undergoes a
transaldimination to form an external aldimine with the amino acid reactant, this
reactant then remains bound to the PLP through the course of the reaction until
a final protonation step allows its release (as part of the product, KDS) and the
reformation of the internal aldimine [30, 36].
Interestingly, phylogenetic analysis of sequences from eukaryotic, archebacterial,
and eubacterial species has shown that a number of different families of PLP
dependent enzymes have distinct evolutionary routes but have converged to have
similar characteristics due to chemical necessities [50]. One difficulty encountered
in designing drugs which target PLP dependent enzymes is due to the prevalence
of PLP dependent enzymes. This has lead to a relatively small number of current
drug targets and approved drugs for such enzymes. However, on-going research
is looking at how this may be overcome, increasing specificity and reducing side
effects [51].
TgSPT itself shows all the typical binding motifs expected for a PLP binding
site, including the heavily conserved three residue His, Ala, Ser motif starting at
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residue 291 which forms a significant part of the binding pocket. Other residues
in the binding pocket are also seen to be present, such as Ser340, though these
are generally less well conserved across the AOS superfamily [33, 36]. However,
although it is likely that the overall fold is conserved in this family of enzymes,
the specific details are in co-factor binding, and protein-ligand interactions are
crucial to exploit structural information for future drug developments.
2.3.2 Known Inhibitors
Figure 6: (I) Sphingosine; (II) Myriocin; and (III) Sulfamisterin.
Another factor which makes SPT a good drug target is the number of known
inhibitors, both synthetic and natural, which make good potential starting points
for drug development. Three such inhibitors are shown in figure 6. Two synthetic
inhibitors, β-chloroalanine and L-cycloserine are also able to inhibit SPT, though
their action is quite general, and they inhibit a wide range of PLP-dependent
enzymes [52, 53]. The most widely used inhibitor is myriocin (ISP-1, thermozy-
mocidin), which comes from the fungus Isalia sinclairii [54]. Its IC50 values for
inhibition in mammalian cells have been shown to be in the nanomolar range.
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For yeast however, the inhibition is much less strong, being in the micromolar
range [55]. The reasons for this are not fully understood, though it is perhaps
down to the action of the Sli1p protein [56].
Yamaji-Hasegawa has reported sulfamisterin, derived from the fungus Pyncini-
diella, which inhibits both mammalian and yeast SPTs, with similar IC50 value
to those of myriocin. They have also reported a number of synthetic deriva-
tives which show varying degrees of inhibition, and give a good starting point for
studying the specific mode of action of this family of inhibitors [57].
2.3.3 Serine Palmitoyltransferase from Sphingomonas paucimobilis
As noted above, the structure of the homologous SPT from S. paucimobilis has
been solved to a resolution of 1.3A˚. This has a 24% sequence homology with the
conserved domain of TgSPT, and is the closest known structure. Figure 7 shows
the homodimer of SpSPT with the PLP internal aldimine shown at the centre of
both subunits. The uses of this analogue are two-fold; firstly it may be of use
in phasing by molecular replacement, though the sequence identity is perhaps a
little low, and it also provides a useful control for any functionality or substrate
binding studies. This structure is, however, not suitable as a starting point for
drug design because the homology is far too low to construct a reliable homology
model based on it. In addition, this protein is from a prokaryotic organism, hence
is very likely to be different in key ways from both the parasite as well as the
human.
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Figure 7: The ∼90kDa homodimer of serine palmitoyltransferase from Sphin-
gomonas paucimobilis [36]. One monomer is shown coloured, and the other grey.
In the coloured monomer α-helix is shown in red; β-sheet in yellow; and random
coil in green. The pyridoxal-5’-phosphate (PLP) cofactor is shown in the centre
of both monomers. (PDB Code: 2JG2)
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3 Supramolecular Protein Assembly
3.1 Heat Shock Proteins
Stress responses in organisms were first noted in 1962 by Ritossa [58] who noted
what he referred to as ‘puffing’ in the salivary glands of Drosophila busckii. A
number of different environmental stimuli are known to cause stress responses such
as heating, desiccation and chemical stress. The proteins associated with these
responses are almost all known as heat shock proteins (HSP) and are ubiquitous
in nature. They are classified further into families according to their molecular
weight (e.g. proteins in the HSP100 will have molecular weights of ∼100kDA).
Their mode of action is to act as molecular chaperones, helping the refolding of
denatured or newly synthesized proteins, or preventing protein aggregation [59,
60].
3.1.1 Small Heat Shock Proteins
Small heat shock proteins are ubiquitous in nature and have been found in all
three kingdoms of life. In the cell, they are known to associate with the nu-
cleus, membranes and the cytoskeleton. The structure of their monomers can
be broken down into three parts: The N-terminal extension; the C-terminal ex-
tension and a conserved ‘α-crystallin’ domain [61]. Whilst the conserved region
acts as a basic building block, it appears that the N-terminal domain acts to
aid oligomerisation [61, 62] and influences sub-unit dymanics and the C terminus
determines the state of the oligomer and influences its stability and chaperoning
function [61, 63, 64, 65].
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3.1.2 Relationship to Human Disease: αB-Crystallin
αB-Crystallin is a heat shock protein and molecular chaperone found both in
high concentrations in the eye [66], as well as at lower levels throughout the rest
of the body, where its expression has been shown to be related to environmental
stress [67, 68, 69]. It serves to provide the majority of the refractive power in
the eye as well as acting to prevent other proteins from aggregating upon heat-
shock and desiccation, keeping the lens clear. A number of mutations in this pro-
tein have been related to the formation of cataracts and myopathy (R120G [70],
450delA [71], 464delCT and Q151X [72]). Recent work has suggested whilst these
mutations do not prevent the function of the protein, they do increase its tendency
to self-associate and aggregate [73].
Figure 8: The truncated structure of human α-B-crystallin published by Bagne´ris
et al. [74] (PDB code: 2WJ7)
The structure of a truncated version of human α-B-crystallin has been published
by Bagne´ris et al. [74] (PDB code: 2WJ7), and is shown in figure 8. The structure
has both N- and C-terminal mutations (detailed in appendix E), and therefore
only shows the conserved α-crystallin domain as a dimer. Other work has used
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cryo-electron microscopy to study the quaternary structure in greater detail [75,
76, 77]. Due, however, to its ready aggregation from solution during and after
purification, it has not been possible to undertake crystallographic studies on
the full-length protein to date, and it is therefore necessary to search out more
stable analogues to get a fuller picture of the tertiary and quaternary structures.
Furthermore, a number of studies have suggested that α-B-crystallin exists in
multiple quaternary structures, which would make crystallisation impossible, as
it relies on monodispersity.
3.2 Heat Shock Protein 16.5 from Methanococcus jannaschii
3.2.1 Methanococcus jannaschii
Methanococcus jannaschii is a hyperthermophilic methanogenic organism which
has been found at deep sea vents [78]. Cultivation of the organism itself proves
rather challenging, as they must be grown at 78 and 100kPa, however proteins
from such organisms are generally found to be more robust and are therefore
well suited to overexpression and purification as well as being more stable for
crystallisation experiments. Its genome was also sequenced relatively early on,
and it was therefore a significant target of the first phase of structural genomics
approaches [79, 80].
3.2.2 Small Heat Shock Protein 16.5 as a Model Protein
A small HSP exists in M. jannaschii (MjHSP16.5)which has homology to α-B-
crystallin. MjHSP16.5 was crystallised and the structure solved to a resolution
of 2.9A˚ by Kim et al. in 1998 [81, 82, 83]. Since then the protein has been the
subject of detailed study, though the full mechanism of its operation is still not
fully understood [84, 85, 86]. Similar deletions to those which cause myopathy and
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cataracts in αB-crystallin have been studied and shown to cause similar behaviour,
though no crystallographic studies have been published to date.
Whilst MjHSP16.5 is only a small protein (147 amino acids, 16452gmol−1) its
functional unit is an octahedron made up of 12 dimers (Figure 30). One of
the 3-fold axes in the octahedron was found to lie on a crystallographic axis,
meaning that the asymmetric unit contained 8 independent monomers. Self-
rotation functions showed that these were further connected by a number of non-
crystallographic symmetry (NCS) axes allowing the use of restraints, simplifying
the refinements and increasing the data:parameter ratio. In the original structure
determination the first 32 amino acids were found to be disordered within the core
of the octahedron, though it has been postulated that these play an important
role in the initial folding of the icositetramer [82, 86].
A number of authors have used MjHSP16.5 as a model system, as well as look-
ing into its general properties as a heat shock protein. Studies have considered
the affects on the packing interfaces and their effect on oligomerisation [87], fac-
tors affecting its polydispersity in solution [88] and the factors affecting subunit
exchange [89]. Through this work, we are now in a strong position to understand
the behaviour of MjHSP16.5. This combined with the ease of its production from
E. coli, and its stability in solution make it an ideal system for model study of
the behaviour of heat shock proteins.
3.2.3 HSP16.5 and αB-Crystallin
There is a 17% sequence identity between MjHSP16.5 and human αB-crystallin
and 31% sequence similarity. The structure of a truncated version of human
α-B-crystallin has been published by Bagne´ris et al. [74] (PDB code: 2WJ7).
Whilst this structure only shows the protein as a monomer, the broad structural
similarities between it and MjHSP16.5 are quite clear, as shown in figure 9. Due
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to its instability and polydispersity in solution, it has however not been possible
to undertake crystallographic studies on the full-length protein to date, and it is
therefore necessary to search out more stable analogues to get a fuller picture of
the tertiary and quaternary structures.
Figure 9: Similarities between structures: the top two images show a monomer of
human α-B-Crystallin as solved by Bagne´ris et al. [74] (PDB code: 2WJ7); the
bottom two images show a dimer of MjHSP16.5. Whilst heavily truncated, the
similarity in form is quite clear between the two. α-helix is shown in red; β-sheet
in yellow; and random coil in green.
18
4 Experimental Background
Over the years a wealth of literature has been published on the various aspects
of protein crystallography. For a broad, yet detailed introduction to the subject
Bernhard Rupp’s recent book on the subject proves a valuable starting point [90].
4.1 Protein Overproduction & Purification
The general thesis of protein overproduction is based upon our ability to ‘hijack’
the natural machinery of a cell for our own purposes. This is generally undertaken
in either bacterial, insect or mammalian cells by the insertion of a plasmid, a
section of circularised DNA, which contains information coding for the gene of
interest as well as a selection of other genes, such as one coding for resistance
to a particular antibiotic or genes coding for a particular system to control the
expression of the gene of interest. Further to this, fusions such as a histidine tag
may be included to aid solubility, reduce toxicity, or allow ready purification.
4.1.1 Plasmid Selection
A wide variety of plasmids are available for a number of different expression sys-
tems, allowing the selection of different fusion proteins and tags to aid overex-
pression and purification, a variety of which are shown in table 1. Most plasmids
used here are from the pET family, which are used for expression in E. coli based
on the T7/lactose system [91]. This is a powerful system which produces the
protein, LacI, which binds to DNA in a particular sequence keeping expression
to a minimal level by physically blocking the action of the DNA polymerase un-
til the addition of D-galactose (or an analog isopropyl-β-D-thiogalactopyranoside
(IPTG)), which inhibits the ability of LacI to bind the DNA, therefore releasing
the DNA and allowing the polymerase to initiate expression. Plasmids also con-
19
Figure 10: Schematic plasmid map of pETz t21a, showing a number of features of
the plasmid, including: kanamycin resistance, the ZTag2-Carrier fusion protein,
the six histidine purification tag and lactose/T7 expression control system.4
tain a ‘multicloning site’. This is a region engineered to contain a wide variety of
different restriction enzyme recognition sites, allowing for easy insertion of coding
sequences with complimentary ends.
4.1.2 Construct Design
A number of considerations are taken into account in designing a gene construct
coding for a protein, or part of a protein, for crystallisation purposes. The two
most important factors are functionality and solubility, as there is little biological
worth in the structure of a non-functional protein, and crystals cannot be grown
if the protein is not soluble. The general aim (where the full length protein
is unsuitable) is to find a minimal, structurally homogenous, functional domain,
which can then be expressed, purified and crystallised. A number of bioinformatics
tools exist to aid in this process such as BLAST [95, 96], which allows ready
4Image courtesy of Gunter Stier, European Molecular Biology Laboratory, Heidelberg.
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Tag Properties
His6 A tag comprising a repeat of six histidines, used
for metal-affinity purification
Strep A tag of eight amino acids (WRHPQFGG) which binds
to streptavidin, and can therefore also be used
for purification [92]
MBP Maltose Binding Protein – Large fusion protein,
which may improve expression levels, and give
proper folding [93]
GST Glutathione S-Transferase – Another large fusion
protein, which may also improve expression levels,
and give proper folding [94]
Table 1: Various commonly used tags and fusion proteins and their properties.
comparison of the protein sequences to others, showing any conserved domains of
the protein, which in general correspond to the functional regions of a protein.
Other computational tools are available to predict the secondary structure (e.g.
Jpred 3 based at the University of Dundee [97, 98]) or find other features such
as transmembrane helices (e.g. HMMTOP based at the Hungarian Academy of
Sciences [99, 100, 101]), giving further information to aid design.
4.1.3 Cloning
Once the desired region has been identified, there are a variety of different strate-
gies available to engineer a system through which the protein of interest can be
produced:
Conventional Directional Cloning uses a combination of restriction and lig-
ation to create a plasmid that may then be used to overexpress this protein. In this
method, forward and reverse primers are designed, which may be used to amplify
the desired region of the cDNA by the polymerase chain reaction (PCR) [102],
while also engineering restriction sites onto the ends of the sequence to allow in-
sertion of the construct into the desired plasmid. A variety of different restriction
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enzymes are available, which cut DNA at a number of different recognition sites.
Cut plasmid and insert with complimentary ends can then be ligated using a T4
DNA ligase and thus reforming the plasmid, allowing it to be inserted into the
cell type of choice.
Topoisomerase Cloning This method exploits the ability of the enzyme DNA
topoisomerase to act both as a restriction and ligation enzyme. This removes the
need for the restriction step; instead recognition sites for the relevant topoiso-
merase are included in the primers used to amplify the protein of interest, which
is then inserted into the plasmid directly from PCR. Furthermore, commercially
available kits contain linearised plasmid with topoisomerase covalently bound to
each 3’ phosphate of the DNA, greatly increasing the speed and efficiency of the
reaction, which in practice only takes around five minutes.
Ligation Independent Cloning This method negates the need for both re-
striction and ligation by exploiting the 3’ to 5’ exonuclease activity of T4 DNA
polymerase in the presence of a single deoxyneucleotide (dNTP) [103]. To do this,
both the insert and the plasmid contain a specific twelve nucleotide end sequence,
lacking one pair of nucleotides. Then, in the presence of the one of the missing
dNPTs (one for the insert and the other one for the plasmid) the T4 DNA ligase
cleaves all the 3’ nucleotides up to the first concurrence of the nucleotides miss-
ing from the end sequence, leaving complementary single stranded DNA. These
overhangs are then long enough to negate the requirement for ligation, being long
enough to anneal independently, and the backbone is then rejoined by the host
DNA repair and expression machinery.
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4.1.4 Overexpression
E. coli strain BL21(DE3) are most commonly used for protein expression. A num-
ber of different variants of the strain are available such as BL21 AI, which contains
an additional layer of expression control to aid in the expression of toxic proteins.
Other variants contain plasmids that supplement the expression machinery, by
introducing rare codons not normally found in E. coli, or coexpressing lysozyme,
to help with cell lysis and extracting the protein of interest.
In standard expression, as the plasmid containing the DNA for the protein
of interest also contains the genes encoding for LacI (see section 4.1.1 for more
details), no protein is expressed until IPTG is added to the growth medium.
Cultures are first grown whilst monitoring their optical density (OD) at 600nm,
giving an indication of the stage of the cells’ growth. Expression is then induced
with IPTG at between OD 0.3 and 0.6, when the cultures are in their exponential
phase, and growing most rapidly. They are then grown for 3hrs, generally at
reduced temperature, after which, cells are harvested by centrifugation.
Figure 11: (I) β-D-Galactopyranoside (D-Galactose) (II) Isopropyl-β-D-
thiogalactopyranoside (IPGT).
Autoinduction For some proteins, standard expression protocols, even with
reduced levels of IPTG, may prove to harsh and can cause problems, particularly
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with solubility. A more gentle way to bring about expression is to use autoinduc-
tion as developed by Studier [104]. This technique relies on the natural response
of E. coli to conditions where there are multiple sources of energy available. In
the case of autoinduction, we use glucose, lactose and glycerol. In the first place,
the cells use the glucose as their food source, and the cell uptake and metabolism
systems relating to lactose metabolism are silenced. However, after a period of
time, the rapidly growing cells use up all the glucose, and the lac operator is
de-repressed. Consequently, the gene encoding the T7 RNA polymerase in our
plasmid is also de-repressed, and our protein begins to be expressed as well.
4.1.5 Purification
The most straight forward route to purification is to design all constructs with
a multi-histidine fusion tag to allow the use of the quick and robust procedure
of nickel affinity chromatography. This tag can then be connected to the protein
by a linker which contains the recognition sequences for a site-specific protease of
which there are a number. Perhaps the most commonly used of these is the 27kDa
NIa protease from the tobacco etch virus (TEV) [105, 106], which recognises the
linear epitopes of the form EXXYXQG or EXXYXQS, cutting between the Q and the G
or the Q and the S. Another commonly used protease is the 3C protease from hu-
man rhinovirus, which recognises sequences of the form LEVLFQP or LEVLFGP [107].
Furthermore, as in both cases the protease is engineered with a His6 tag, the cleav-
age reaction mixture can once again be passed over a nickel affinity column, and
thereby all protease, cleaved tag, uncleaved fusion protein and other impurities
with nickel binding sites is removed from the mixture, leaving the cleaved protein
of interest pure.
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4.2 Crystallisation
Crystallisation occurs when a protein becomes oversaturated in solution making
nucleation a more favourable process. Due to the instability of proteins in solu-
tion, this is a difficult process to undertake with aggregation being a significant
difficulty. As such it is necessary to find a condition in which the protein is
more stable as its concentration increases. A number of different techniques are
used to promote such a situation and a detailed handling of these can be found
in Terese Bergfors’ book on the subject [108]. A general scheme would involve
an initial high-throughput screen using a crystallisation robot [109] followed by
rounds of optimisation of positive conditions to yield better crystals. Whilst vi-
sual inspection may give an immediate feedback of the suitability of conditions,
in-house testing of crystals grown is used to identify the best conditions for X-ray
diffraction.
The most common technique used for protein crystallisation is vapour diffusion.
Small (0.05-10µl) droplets are made containing similar volumes of a concentrated
protein solution and of a crystallisation solution which is usually made up of a
buffer, a precipitant and often some kind of additive such as a salt. These are
then sealed along with a much larger reservoir of the crystallisation solution. Over
time the system equilibrates, changing the concentration in the drop and, in the
preferred scenario, promoting crystallisation.
The use of such high-throughput screening methods has vastly improved the
speed and possibility of protein structure determination. Whereas previously the
amount of time available has constrained the ability to tackle more challenging
structures, it is now entirely possible to set-up over 1000 crystallisation experi-
ments in an afternoon’s work, removing a significant bottleneck to progress. In-
deed, the design of such screens has become a science in itself, bringing in to play
such ideas as genetic algorithms and factorial design increasing success rates still
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further.
4.2.1 Cryoprotection
Figure 12: Two cryoprotectants: (I) Glycerol and (II) 2-methyl-2,4-pentanediol
(MPD).
In order to reduce dynamic disorder and slow down radiation damage (by de-
creasing the mobility of radical species created), data are collected at 100K [110].
This can lead to the formation of ice within crystals, reducing data quality, and
potentially destroying the crystal. To prevent this a selection of different ’cryopro-
tectants’ are used, such as glycerol and 2-methyl-2,4-pentanediol (MPD) (Figure
12). These may either be included in the crystallisation solution as the precipitant
or where this is not possible the crystal may be incubated in a suitable solution
before freezing [111].
4.3 X-Ray Diffraction
4.3.1 The Ideal Crystal
An idealised crystal consists of regular arrays of atoms and molecules which repeat
infinitely throughout the solid. As such, one can describe the crystal by its ‘unit
cell’; the most simple repeat unit within a crystal, being defined by six parameters;
three angles (α, β and γ), and three dimensions (a, b and c), such that α lies
between b and c, opposite a etc.. Further to this, one can define planes within
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Figure 13: A schematic representation of a unit cell.
the crystal which repeat infinitely. These are defined by the Miller indices h, k
and l. A plane h, k, l intercepts the unit cell axes at points a/h, b/k and c/l. By
convention, negative indices are written as n¯ for −n. Indices are also expressed
such that the greatest common divisor is 1.
4.3.2 Bragg Diffraction
Figure 14: A schematic representation of Bragg diffraction.
As observed by von Laue, a beam of X-rays may be diffracted when passing
through a crystal. This occurs due to the interaction between the X-ray and the
electrons in the solid. Bragg peaks occur when the X-rays are scattered in phase
(when an integer number of waves fit between two Miller planes), as any other
interference would interact destructively. The net effect of this gives rise to the
discrete pattern of spots observed on a diffractogram. The relationship between
the wavelength of X-rays used (λ), the spacing between planes (dhkl) and the angle
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between the plane and the diffracted beam (θ) is defined by the Bragg equation:
λ = 2dhkl sin θ (1)
4.3.3 Space Groups
We have already considered a representation of the translational symmetry in
a crystal in terms of three angles (α, β and γ) and three dimensions (a, b and
c). While in theory an infinite number of different unit cells might be defined
for a particular crystal a number of conventions exist which allow a standardised
representation. For instance, in a system where a 6= b 6= c and α 6= β 6= γ
there is no metric symmetry within the unit cell and the system is said to be
triclinic. At the opposite extreme, a crystal where and a = b = c and α = β = γ
must contain four three-fold rotation axes and is said to be cubic. In all seven
crystal systems are defined. These are further subdivided into fourteen ‘Bravais
lattices’ on a basis of the position of lattice points within the cell. Lattices can be
either primitive P , where lattice points only exist at the corners of the cell, body
centered I, face centered F , where an extra lattice point exists on each face of
the cell or centred on a single face A, B or C, though it is important to note that
not all combinations are unique. These are then further subdivided on a basis
of internal symmetry operations, such as mirror planes and rotation axes, into a
total of 230 space groups, which are listed in [112].
This picture can be simplified somewhat for protein crystallography. Proteins
are enantiomerically pure, being composed entirely from L-amino acids, a mirror
plane or an inversion operation would transform the protein to the D- form which
does not occur naturally. As such, protein structures are restricted to non-mirror
and non-inversion symmetry operations. This reduces the number of space groups
available to the 65 chiral space groups.
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4.3.4 The Structure Factor
In the diffraction experiment we measure the intensity, Ihkl, of a set of reflections.
Certain corrections are applied to these to give a concept, the structure factor
Fhkl:
Ihkl = |Fhkl|2 · LP · A (2)
Where LP represents a polarisation and geometry correction and A an absorption
correction. In turn, in a simplified picture of a crystal, Fhkl may be related to the
contents of the unit cell by the Fourier transform:
Fhkl =
atoms∑
j
fj(θ) exp[2pii(hxj + kyj + lzj)] (3)
=
atoms∑
j
fj(θ) cos[2pi(hxj + kyj + lzj)] +
atoms∑
j
fj(θ) sin i[2pi(hxj + kyj + lzj)] (4)
Where fj(θ) is a function relating the scattering power of each atom in relation
to the scattering angle 2θ (the angle between the incident and diffracted beam)
and xj, yj and zj are the fractional coordinates of each atom in the unit cell.
4.3.5 Systematic Absences
Depending on the particular symmetry within a crystal its diffraction pattern
may display certain systematic absences; expected Bragg peaks which are not
observed. These are where geometry within a crystal causes certain reflections
to have an intensity of zero. Well established rules can tell us where we might
see systematic absences. For instance, in the body centered cubic system, for a
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monatomic crystal equation 3 reduces to the following two cases:
Fhkl =

2fj(θ), h+ k + l even
0, h+ k + l odd
(5)
Many other crystallographic features, such as screw axes, glide planes and other
forms of centering also have systematic absences associated with them. The com-
bination of this information with the unit cell parameters determined can be used
to help identify the particular space group of the crystal’s unit cell.
4.3.6 Electron Density
The exact relationship between the electron density and the diffraction pattern
can be described by a Fourier transform:
Fhkl =
∫
cell
ρ(xyz) · exp[2pii(hx+ ky + lz)]dV (6)
with ρ(xyz) being a continuous positive function representing the electron density
in terms of the fractional coordinates x, y and z. This represents a very compli-
cated function to compute, and is simplified by treating the structure as being
composed of discrete spherical quantities as in equation 3. This reduces equation
6 to the summation:
Fhkl =
∑
j
fj(θ) · exp(−8pi2Uj sin2 θ/λ2) · exp[2pii(hxj + kyj + lzj)] (7)
where fj(θ) is the atomic scattering factor, and Uj a displacement parameter, rep-
resenting the mean squared displacement of a particular atom. In cases where suf-
ficient data are available this may be further improved by the use of an anisotropic
displacement matrix, allowing for different displacement in three directions, mod-
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elling each atom’s displacement with an ellipsoidal probability distribution.
Equation 6 can also be restated in terms of ρ(xyz), giving us an expression for
the electron density which is the physical quantity we aim to measure, and from
which we infer the position of the individual amino acids. This is the reverse
Fourier transform of the diffraction pattern, however unlike equation 6, because
the diffraction pattern is made up of discrete reflections, rather than a diffuse
pattern, the Fourier transform is immediately a summation:
ρ(xyz) =
1
V
∑
h,k,l
Fhkl · exp[2pii(hx+ ky + lz)] (8)
4.3.7 The Phase Problem
Every diffracted wave has both an amplitude and a phase. In the diffraction
experiment we are only able to measure the amplitudes. Likewise, the structure
factors may be considered as vectors for which only the magnitude is known, in
the absence of any phase information. An analogy to this situation might be to
consider being given a copy of a poem without indication of in what order the
words are to be placed; any number of combinations are possible, but only certain
will make any sense, and with luck one might make significantly more sense than
any other. For this reason we must use some prior knowledge to aid our solution.
Mathematically this is seen by restating equation 8 with explicit statement of
the phase information contained within Fhkl:
ρ(xyz) =
1
V
∑
h,k,l
|Fhkl| · exp[iφ(hkl)] · exp[2pii(hx+ ky + lz)] (9)
4.3.8 The Patterson Method
In a Patterson synthesis, we replace the corrected observed amplitudes |Fo| with
their squares. This effectively sets all phases to zero. The consequences of this are
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seen in the following equation which may be derived from equation 9, by making
this change:
P (uvw) =
1
V
∑
hkl
|F (hkl)|2 cos[2pi(hu+ kv + lw)] (10)
The result of this new Fourier synthesis is no longer the electron density, but
instead a function P (uvw). This holds many similarities to an electron density
distribution; its coordinates are still fractions of the unit cell parameters and it
is a continuous function repeated in each unit cell. However, its peaks no longer
represent the positions of individual atoms, instead they represent vectors between
pairs of atoms in the structure, their heights being proportional to the product
of the atomic numbers of the two atoms. Due to a convolution effect the peaks
in the Patterson function are twice as wide as those in the corresponding electron
density map leading to an often indistinguishable mass of peaks.
Where heavy atoms are present in the structure, their contribution to the Pat-
terson function is more pronounced than those of lighter atoms. This can give us
information about the positions of these atoms allowing the calculation of basic
phases. From these it is often possible to discern further features in the electron
density map leading to cycles of map improvement followed by phase improve-
ment, giving a full structure solution.
4.3.9 Molecular Replacement
Another technique for finding atomic positions in the unit cell from a Patterson
synthesis is the use of a known molecular fragment to calculate a set of peaks
which can then be found within the Patterson map, leading to phase information.
This is of particular use in protein crystallography, where the technique is known
as molecular replacement, as evolution has kindly lent us a sets of similar proteins.
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Where the structure is already known for a protein with a sequence identity of
∼30% or above, this structure might be used to make rotation and translation
searches of the Patterson function again giving phase information [113, 114, 115].
4.3.10 Single/Multiple Isomorphous Replacement
A difficulty encountered in the use of the Patterson method in protein crystallog-
raphy is the general lack of heavy atoms. In some cases, for instance haemoglobin,
these are already present and allow solution more readily, but often it is necessary
to introduce them to a material. Indeed, even in the case of haemoglobin it may
prove difficult to identify the location of the haem group due to the very large
number of other atoms present. Two general strategies exist to pursue this. The
first involves the initial growth or later ‘soaking’ of crystals in a solution contain-
ing a particular heavy atom additive which might then bind preferentially to a
particular site in the crystal. The second involves the introduction of the heavy
atom directly into the protein by the substitution of the sulphur containing amino
acid methionine with its selenium derivative.
In both cases the we are left with two datasets, one with the heavy atom and
one without. If the two materials are isomorphous, it is possible to calculate
the contribution of the heavy atoms to the diffraction and thus determine their
positions quite accurately, allowing the calculation of phase information relating to
the heavy atoms. Now consider the structure factors as vectors. An isomorphous
replacement experiment with one derivative gives us the following equation:
Fderivative = Fprotein + Fheavy atom (11)
As we know the magnitude of each vector and the orientation of Fheavy atom there
are two possible solutions for the orientation of Fprotein. If we further prepare a
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second derivative, we will have a second equation allowing for the unambiguous
solution of the phase information.
4.3.11 Single/Multiple Anomalous Diffraction
For light atoms the function fj(θ) may be considered as constant with respect
to the wavelength of the radiation used. For heavier atoms (those heavier than
sulphur), this is not the case. Around their X-ray absorption edge, there is a
distinct change in their scattering power with change in energy due to resonance
between the X-ray waves and electronic transitions from bound atomic orbitals.
This may be considered as:
f totalj (θ, λ) = f
0
j (θ) + |f∆j (λ)|eiδ (12)
= f 0j (θ) + f
′
j(λ) + if
′′
j (λ) (13)
Where f 0j (θ) is the normal scattering factor, f
∆
j (λ) the anomalous scattering
factor and f ′ and f ′′ the real and imaginary components of the scattering factor.
Two datasets collected either side of the absorption edge would therefore give dif-
ferent values of Fhkl, the differences relating to the anomalous diffraction, leading
to a similar situation as above, giving further phase information [116]. The values
of f ′ and f ′′ may be obtained from X-ray absorption spectra by the relationship:
f ′′(E) ∝ E · µa(E) (14)
Where µa is the atomic absorption coefficient and E the energy of the X-ray
wave. Real values may then be obtained by Kramers-Kronig transformation from
f ′′ values [117].
The most common element used for anomalous diffraction experiments is sele-
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nium as outlined in Section 4.3.10. Indeed in seeking to combine as much infor-
mation as is available, a general scheme would normally involve combinations of
both isomorphous replacement and anomalous diffraction.
4.3.12 Data Reduction
With the advent of CCDs for data collection, crystallographers moved away from
directly measuring the intensity of each reflection, and it is therefore necessary
to calculate the intensity of each spot using a process know as data reduction.
This first involves harvesting spots on frames and indexing them. Indexing is
the process of assigning the Miller indices to each reflection, which first requires
the determination of the unit cell of the material and the orientation matrix of
the crystal (relating the laboratory axes (xyz) to the internal axes of the crystal
(abc)). As each reflection is spread across a number of frames, it is then necessary
to integrate and merge each of them. This process involves fitting a profile to
each spot allowing the calculation of the total intensity across all frames for each
reflection. Certain corrections are applied to the data to account for factors such
as absorption in the crystal and the size of the crystal giving a final intensity for
each reflection.
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5 Materials & Methods
5.1 Bioinformatics
Gene databases were searched using the Basic Logical Alignment Search Tool
(BLAST) web-server [95, 96], which shows regions of homology between the sub-
mitted sequence and other known proteins. Protein structures were searched using
the RSCB PDB [118]. More detailed sequence alignments were performed using
the EBI ClustalW web-server [119, 120, 121].
Basic secondary structure features were identified using the Jpred 3 web-server [97,
98], and transmembrane helices identified using the HMMTOP web-server [101,
100]. Properties of potential constructs such as mass, amino acid composition,
theoretical pI, and theoretical stability were calculated using the ExPASy Prot-
Param web-server [122, 123].
Homology models were calculated using MODELLER [124]. Protein sequences
were used in searches for similar sequences in the PDB [118], and the sequence
with the highest similarity used to calculate the model. All models were analysed
and least-square superpositions were performed with Coot [125].
5.2 Standard Cloning & Expression
Work performed at Durham followed a standard low-throughput DNA cloning
and protein overproduction strategy. Plasmids were synthesised through PCR,
restriction, and ligation. Expression was trialled on the decilitre scale, and large-
scale expression undertaken on a litre scale.
5.2.1 DNA Synthesis & Cloning
Cloning was undertaken in the E.coli strain DH5α. Small quantities of plasmid
were obtained and purified using the Qiagen Spin MiniPrep system with a Sigma
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Table 2: Examples of DNA primers used for the cloning of truncated TgSPT
constructs.
Name Sequence
5NcoITgSPT47 CATG CCATGG CC AACGACGAAGTGAGCTGG
5NcoITgSPT181 CATG CCATGG CC CCTTTCGCCTACGAAGTCT
5HindIIITgSPT181 CCC AAGCTT GC CCTTTCGCCTACGAAGTCT
3NotITgSPT STOP ATAAGAAT GCGGCCGC TTA TCGGAGCATGTCAGTGGGTGGG
1-14 microcentrifuge, and larger quantities using the Spin MidiPrep system with
a Boeco U320 centrifuge. Linear DNA was purified by the QIAquick PCR Prod-
uct Purification system with a Sigma 1-14 microcentrifuge. FideliTaq from the
USB Corporation was used for proof-reading PCR and Promega GoTaq for more
general screening purposes. All primers were ordered from Sigma-Aldrich. T4
DNA ligase and all restriction enzymes were from Promega. Throughout the
BioRad Sub-cell GT agarose gel electrophoresis system was used for analysing
DNA samples. Ligation reactions were incubated for 16h at 4, and then used
to transform SoloPack Gold cells from Strategene by heat shock at 42 for 90s
following the manufacturer’s standard protocol. Positive cell lines were then iden-
tified by colony PCR. The presence of correctly ligated insert was further verified
by restriction digestion analysis and DNA sequencing.
5.2.2 Protein Overproduction & Purification
Various expression strains were trialled for protein expression, and are tabulated
in table 3. Chemically competent cells were transformed with plasmid after incu-
bation on ice with the plasmid for 30 minutes by heat shock at 42 for 90 seconds,
incubation on ice for 2 minutes, followed by the addition of 1250µl of SOC (Su-
per Optimal Broth with Catabolite Repression: Tryptone (pancreatic digest of
casein) 2% (w/v), Yeast Extract 0.5% (w/v), NaCl 8.6 mM, KCl 2.5 mM, MgSO4
20 mM, Glucose 20 mM), and incubation with shaking at 120 rpm at 37 for one
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Expression Strain Producer Features
BL21(DE3) Invitrogen Standard T7 expression strain
BL21(DE3)pLysS Promega BL21(DE3) expression strain, but with an
additional plasmid encoding for T7 lysozyme,
to lower background expression levels of
target genes
BL21-AI Invitrogen BL21(DE3) expression strain, but with the
T7 RNA polymerase gene controlled by the
araBAD promoter, preventing expression
without the presence of arabinose, reducing
background expression of target genes
BL21-CodonPlus Stratagene BL21(DE3) expression strain, but
with additional copies of tRNAs which are
rare in E. coli
Tuner EMD lacZY deletion mutant of BL21(DE3),
allowing regulation of expression levels
by varying the concentration of IPTG
Rosetta EMD Tuner expression strain, including
additional copies of tRNAs which are
rare in E. coli
Rosetta-pLysS EMD Rosetta expression strain, with
an additional plasmid encoding for T7
lysozyme to lower background expression
levels of target genes
Table 3: Details of various cell lines used for standard expression screening, and
protein production.
hour, before spreading on LB (Luria Bertani Broth: Tryptone (pancreatic digest
of casein) 10 g/L, Yeast Extract 5 g/L, NaCl 5 g/L) agar plates, and incubation
overnight at 37. For large scale IPTG-induced expression, 1l flasks of LB, and
the appropriate antibiotic(s) were then inoculated with 1ml of overnight culture
and grown at 37 with shaking at 120 rpm, and their OD 600nm monitored.
Cultures were induced when they reached an OD of 0.4 by the addition IPTG to
a final concentration of 1mM and grown at various temperatures for 3 hours. Cells
were harvested by centrifugation in a Beckman Coulter Avanti J-20XP centrifuge
at 5000×g for 15 minutes.
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Autoinduction Some large-scale cultures were also grown by autoinduction.
The composition of media used was the same as was described by Studier in
2005 [104]. Inoculated 1l cultures were grown at 37 with shaking at 120 rpm,
until their OD at 600nm reached 0.5, at which point their temperature was reduced
to 20. Cells were harvested by centrifugation in a Beckman Coulter Avanti J-
20XP centrifuge at 5000×g for 15 minutes.
Pellets were resupended in a lysis buffer containing EDTA-free protease inhibitor
cocktail from Roche. Cell lysis was performed by 6 cycles of sonication with a
Sanyo Soniprep 150 (30s on, 30s off) on ice. Cell debris was then harvested by
centrifugation at 25,000×g for 20mins. Crude lysate was then filtered through
0.45µm and 0.22µm filters. Nickel affinity purification was performed using a GE
Healthcare A¨KTA Explorer with 5ml HisTrap FF columns. Proteins were first
bound to the column under low imidazole concentration (10mM) and then eluted
over an increasing imidazole gradient (10–1000mM). Absorbance at 280nm was
measured to identify fractions containing protein which were then pooled and
dialysed overnight with remove imidazole. Where tag cleavage was required, the
appropriate protease was included with the protein for dialysis, and a second nickel
affinity purification was undertaken, uncleaved protein, fusion tag and protease
remaining bound to the column with cleaved protein in the flow-through. Protein
samples were then analysed by SDS PAGE, using the Bio-Rad Mini-PROTEAN
Electrophoresis system.
5.3 High-throughput Expression Screening
High-throughput work was undertaken at the Oxford Protein Production Facil-
ity at the Harwell Science and Innovation Campus in Oxfordshire. The work is
based a on 96-well plate format, generally producing 48 different constructs of
varying length in purpose made vectors of the ‘pOPIN’ series. Cut vector and in-
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Vector Parent Vector Features
pOPINE pTriEx2 C-terminal His6 tag.
pOPINF pTriEx2 3C-protease-cleavable His6 tag.
pOPINJ pTriEx2 3C-protease-cleavable His6 and GST tag.
pOPINS3C pET28a 3C-protease-cleavable His6 and SUMO tag.
Table 4: Details of the four vectors used for the high throughput expression
screening protocols.
Vector Extension
pOPINE Forward AGGAGATATACCATG
Reverse GTGATGGTGATGTTT
pOPINF Forward AAGTTCTGTTTCAGGGCCCG
Reverse ATGGTCTAGAAAGCTTTA
pOPINJ Forward AAGTTCTGTTTCAGGGCCCG
Reverse ATGGTCTAGAAAGCTTTA
pOPINS3C Forward GCGAACAGATCGGTGGT
Reverse ATGGTCTAGAAAGCTTTA
Table 5: Details of the InFusion primer extensions for each of the four vectors
used for the high throughput expression screening protocols.
sert are combined using the InFusion system of ligation-independent cloning from
Clontech. Expression screening is then undertaken on a 2.5ml scale using IPTG
and autoinduction in two different expression strains. Purification uses a Qiagen
BioRobot 8000 with Ni-NTA magnetic beads.
5.3.1 DNA Synthesis & Cloning
Constructs were designed using the standard set of bioinformatics tools as de-
scribed in section 5.1, and primers designed with specific extensions for each
vector used. Details of the four vectors used are shown in tables 4 & 5.
Template Amplification by PCR PCR reactions were undertaken in a Veriti
96-well thermal cycler from Applied Biosystems. Initial reactions were undertaken
using KOD Xtreme Hot Start DNA Polymerase Mastermix from Novagen, using
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the manufacturer’s standard protocol. A second round of reactions was under-
taken using Phusion Flash Mastermix from New England Biolabs and used for
conditions which had not amplified well with the KOD Xtreme. PCR products
were then analysed by agarose gel electrophoresis using a 1.25% TBE/agarose
gel using 4µl of Hyperladder I from BioLine as reference, and SYBRSafe Stain
from Invitrogen for visualisation under UV light, and were loaded using 0.25%
w/v bromophenol blue in 30% v/v glycerol as a loading buffer (5µl product to 2µl
buffer). Following removal of the template DNA by treatment with DpnI, the am-
plified DNA was then purified using the Agencourt AMPure XP magnetic bead
purification system from Beckman Coulter, using the manufacturer’s standard
protocol.
Ligation Independent Cloning InFusion reactions were performed using lyoph-
ilised enzyme and buffer from the manufacturer, with 100ng of template and be-
tween 10 and 250ng of purified insert in a 20µl reaction volume. Reactions were
then held at 42 in the Veriti thermocycler. After 30 minutes the reactions were
transferred onto ice, and diluted with 40µl TE buffer (10mM Tris pH 8.0, 1mM
EDTA). 5µl aliquots of these reactions were then transformed immediately into
OmniMax II chemically competent cells from Invitrogen, by 30 second heat-shock
after 30 minutes incubation on ice. Cells were then returned to ice for 2 minutes
before the addition of 300µl of Power Broth from Molecular Dimensions. These
were then incubated without shaking for 1 hour at 37.
24-well agar plates were then prepared (2 wells for each reaction) with 1ml of
LB agar, including the appropriate antibiotic, as well as X-gal and IPTG to allow
for blue-and-white screening. Before plating out the cells, 20µl of Power Broth
was added to each well, to allow for an even spread of colonies. Then for each
reaction 5µl and 20µl of the concentrated cells at the bottom of the unshaken
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transformation tubes were added to two separate wells. The plates were then
shaken vigorously, and left to dry for 15 minutes, before incubation upside-down
overnight at 37.
Verification of Colonies If the reactions have been successful, then blue colonies
should only account for 10% of all colonies. If this is the case, then two colonies
are picked for each construct, leading to a roughly 95% success rate. Due to the
use of blue-and-white screening, it is generally felt safe to purify the plasmids
before verification PCR.
Deep well blocks were prepared with 1.5ml of Power Broth, and the correct
antibiotic. White colonies were then picked by touching them with 200µl pipette
tips, and leaving them to stand in the Power Broth for a short while. The filled
plates were then sealed with gas-permeable seals, and shaken at 200 rpm at 37
overnight. Glycerol stocks were produced and stored at -80 by addition of 100µl
of the overnight culture to 100µl 30% v/v glycerol. The cells from the remaining
overnight culture were then harvested by centrifugation for 15 minutes at 5000Ög
using a Beckman Coulter Avanti centrifuge with JS5.3 rotor, the supernatant then
being decanted off.
Plasmids were then purified using the Promega Wizard SV 96 Plasmid DNA
Purification system on the Qiagen BioRobot 8000, following the manufacturer’s
protocol, and verified again using KOD Xtreme Hot Start DNA Polymerase Mas-
termix from Novagen, and the same method of visualisation as previously.
5.3.2 Protein Overproduction & Purification
Transformation into Expression Strains Two different expression strains
were trialled: B834(DE3) and Rosetta(DE3)LysS. Chloramphenicol must be used
if the pRARE-LysS functionality is required to be kept. Transformation is under-
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taken using the same procedure as previously, but with 3µl of purified plasmid
being added to 50µl of competent cells, and only one well used per transforma-
tion, with 30µl of cells being plated out (it does not prove so vital to pick a single
colony, as the purified plasmid was prepared from a single colony, though single
colonies are still desirable).
Expression Testing with IPTG Induction Individual colonies were picked
using 200µl pipette tips, and used to inoculate 0.5ml of Power Broth, supple-
mented with 1% w/v glucose and the appropriate antibiotic, in 96-well deep well
plates. These were then sealed with gas-permeable seals, and grown overnight at
37 with shaking at 240 rpm.
A set of 24-well deep well plates were then prepared with 2.5ml of Power Broth,
supplemented with 1% w/v glucose and the appropriate antibiotic. These were
then inoculated with 62.5µl of the overnight culture, and grown at 37 with
shaking at 240 rpm for 3-5 hours, until the OD at 595nm was roughly 0.5. 12.5µl
of 100mM IPTG in water was then added to each well, to give a final concentration
of 0.5mM, and the cultures were grown overnight at 20 with shaking at 200
rpm. The cultures were then transferred back to 96-well deep well blocks, and the
cells were harvested by centrifugation for 15 minutes at 5000Ög using a Beckman
Coulter Avanti centrifuge with JS5.3 rotor, the supernatant then being decanted
off.
Expression Testing with Autoinduction As with IPTG, individual colonies
were picked using 200µl pipette tips, and used to inoculate 0.5ml of Power Broth,
supplemented with 1% w/v glucose and the appropriate antibiotic, in 96-well deep
well plates. These were then sealed with gas-permeable seals, and grown overnight
at 37 with shaking at 240 rpm.
A set of 24-well deep well plates were then prepared with 2.5ml of Overnight
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Express Instant TB Medium from Novagen and the appropriate antibiotic. These
were then inoculated with 62.5µl of the overnight culture, and grown at 37 with
shaking at 240 rpm for 3-5 hours, until the OD at 595nm was roughly 0.5. The
temperature was then reduced to 25 and the cultures were grown overnight
with shaking at 200 rpm. The cultures were then transferred back to 96-well
deep well blocks, and the cells were then harvested by centrifugation for 15 min-
utes at 5000Ög using a Beckman Coulter Avanti centrifuge with JS5.3 rotor, the
supernatant then being decanted off.
Purification Cell pellets were held at -80 for a minimum of 20 minutes to aid
efficient cell lysis, and were then thawed and resuspended in 210µl of lysis buffer
(50 mM NaH2PO4, 300 mM NaCl, 10mM imidazole, 1% w/v Tween 20 pH 8.0),
supplemented with 1mg/ml lysozyme and 3 units/ml of Benzonase from Merck.
After allowing 30 minutes for lysis to occur, lysate was collected by centrifugation
for 30 minutes at 5000Ög at 4 using a Beckman Coulter Avanti centrifuge
with JS5.3 rotor. The supernatant was then transferred to microtitre plates and
purified using the Qiagen BioRobot 8000 with Qiagen Magnetic Ni-NTA beads,
following the manufacturer’s standard protocol.
10µl of each purified protein was then mixed with 10µl of SDS PAGE loading
buffer (100mM Tris pH6.8, 4% w/v SDS, 0.2% w/v bromophenol blue and 20%
v/v glycerol), and then heated to 90 for 3 minutes to denature proteins. These
were then loaded and analysed using the Novex NuPAGE SDS-PAGE Gel System
from Invitrogen, following the manufacturer’s instructions. Insoluble lysate also
was resuspended in 8M urea buffered with 100 mM NaH2PO4 and 10 mM Tris to
pH 8.0 to allow analysis by SDS PAGE similarly.
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5.4 Protein Analysis by Western Blot
Proteins were transferred from an unstained polyacrylamide gel to an Immobilon
membrane from Millipore using a BioRad Trans-Blot SD Semi-Dry Transfer Cell,
and following the manufacturer’s standard procedure. The standard transfer
buffer was used (5.82g Trizma Base, 2.93g glycine, 200 ml methanol, made up
to 1L with deionised water), polyacrylamide gels being equilibrated in transfer
buffer for five minutes before being sandwiched between two pieces of blot paper
soaked in the transfer buffer and run in the transfer unit at 400mA for 1 hour.
BioRad Precision Plus ‘Kaleidoscope’ Protein Prestained Standard was used as a
molecular weight marker, and to give visual verification of transfer to the Immo-
bilon membrane. The membrane was then blocked by soaking in 3% w/v bovine
serum albumin for 30 minutes to prevent non-specific binding of the antibody to
the membrane.
All proteins detected using Western Blot were expressed using the GE Health-
care pGEX system, and so goat polyclonal anti-GST antibodies from GE Health-
care were used. The secondary antibody is then an anti-goat IgG horseradish
peroxidase, again from GE Healthcare, allowing visualisation by a combination of
chemiluminescent probe (luminol), and photographic film.
5.5 SPT Functionality Assays
Chemically competent BL21-AI were transformed with pET24a empty plasmid as
a negative control, pET24a including the gene for the expression of each construct
for testing, and pET16b containing the gene for the SPT from S. paucimobilis as
a positive control, and overnight cultures grown from single colonies using the
procedure described above. 150µl of each of these was then used to inoculate
15ml cultures of LB in 25ml conical flasks with the correct antibiotic. These
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were then grown with shaking at 120 rpm at 37until their OD at 600nm was
at 0.4, at which point expression was induced by the addition of IPTG to a final
concentration of 1mM and L-arabinose to a final concentration of 0.2% w/v. These
were then grown for a further hour with shaking at 120 rpm at 37 and then
harvested by centrifugation at 2000Ög for 10 minutes.
The cells were then resuspended in phosphate buffered saline supplemented with
2.5µCi of 14C-serine (a small sample of the pellet was kept to check expression
levels by SDS PAGE), and grown for a further hour with shaking at 120 rpm at
37. The cells were then harvested by centrifugation at 6000Ög for 10 minutes,
resuspended in 1ml of 10:10:3 chloroform:methanol:water, and vortexed with a
small amount of glass beads for 5 minutes. The lysate was then centrifuged at
14000Ög for 10 minutes, and the lower organic phase carefully extracted using a
fine tipped Pasteur pipette.
Samples were then concentrated for 5 minutes in an Eppendorf 5301 VacuFuge at
30, and analysed using thin layer chromatography, using Merck HPTLC Silica
Gel 60 plates, with chloroform:methanol:ammonium hydroxide, 40:10:1, as the
solvent. The plates were then visualised using autoradiography on photographic
film.
5.6 Solubility Screening
Solubility screening was undertaken as described by Jancarik in 2004 [126]. Ta-
ble 6 shows the buffer conditions used for initial screening of protein stability.
When more stable conditions had been identified, the use of additives such as
DTT, NaCl, and glycerol was tested, and pH varied, in order to find the most
stable buffer conditions for each protein.
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No. Buffer pH
1 Glycine 3
2 Citric acid 3.2
3 PIPPS 3.7
4 Citric Acid 4
5 Sodium acetate 4.5
6 Sodium/potassium phosphate 5
7 Sodium citrate 5.5
8 Sodium/potassium phosphate 6
9 Bis-tris 6
10 MES 6.2
11 ADA 6.5
12 Bis-tris propane 6.5
13 Cacodylate 6.5
14 Ammonium acetate 7
15 MOPS 7
16 Sodium/potassium phosphate 7
17 HEPES 7.5
18 Tris 7.5
19 EPPS 8
20 Imidazole 8
21 Tris 8.5
22 CHES 9
23 CHES 9.5
24 CAPS 10
Table 6: The composition of buffers used in the optimum solubility screen. Each
had a concentration of 100mM.
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5.7 Crystallisation
High throughput screening was undertaken using a Screenmaker 96+8 Xtal from
Innovadyne Technologies Inc. to produce sitting drops. This tests 96 different
crystallisation solutions at a time, each with 2 drops of different concentration
(Sitting drops, 100nl of crystallisation solution with 100nl of protein solution and
200nl of crystallisation solution with 100nl of protein solution). Trays were then
incubated at 18 and any crystal growth was monitored.
Figure 15: The Screenmaker 96+8 Xtal from Innovadyne Technologies Inc. is
use to produce nanolitre-scale crystallisation experiments, for high-throughput
screening of crystallisation conditions.
Larger scale hanging drop vapour-diffusion crystallisation experiments were set
up by hand on a µl scale, with 1ml reservoirs. Drops were set up with a variety
of ratios of protein solution to reservoir solution, in order to vary protein and
precipitant concentration. Trays were mainly incubated at 18, though some
were also incubated at higher and lower temperatures. Drops were monitored
daily for two weeks, and less frequently thereafter. The typical crystallisation
experiment used for the HSPs is shown in table 7.
48
0.02M Calcium Chloride 0.02M Calcium Chloride 0.02M Calcium Chloride
25.0% 2-Methyl-2,4-pentanediol 25.0% 2-Methyl-2,4-pentanediol 25.0% 2-Methyl-2,4-pentanediol
0.20M Sodium Acetate pH 5.5 0.25M Sodium Acetate pH 5.5 0.30M Sodium Acetate pH 5.5
0.02M Calcium Chloride 0.02M Calcium Chloride 0.02M Calcium Chloride
27.5% 2-Methyl-2,4-pentanediol 27.5% 2-Methyl-2,4-pentanediol 27.5% 2-Methyl-2,4-pentanediol
0.20M Sodium Acetate pH 5.5 0.25M Sodium Acetate pH 5.5 0.30M Sodium Acetate pH 5.5
0.02M Calcium Chloride 0.02M Calcium Chloride 0.02M Calcium Chloride
30.0% 2-Methyl-2,4-pentanediol 30.0% 2-Methyl-2,4-pentanediol 30.0% 2-Methyl-2,4-pentanediol
0.20M Sodium Acetate pH 5.5 0.25M Sodium Acetate pH 5.5 0.30M Sodium Acetate pH 5.5
Table 7: The well composition of the typical hanging drop vapour diffusion crystallisation experiment used for to the
crystallisation of the heat shock proteins. It is based on the conditions published by Kim et al. [81]. Multiple drops were
then suspended above each well, typically three, having compositions (well solution : protein solution) of 2:1, 1:1 and 1:2.
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5.8 Data Collection at Durham
Initial testing of crystals was performed using Cu Kα radiation (λ=1.54184A˚) on
a Bruker Microstar rotating anode with a three circle goniometer and a Platinum
135 CCD area detector. φ and ω scans were used to sample reciprocal space for
initial matrix determination. An Oxford Cryosystems Cobra was used to cool all
crystals to 100K. Crystals were mounted in Hampton cryoloops with magnetic
bases.
5.9 Data Collection at DLS
Synchrotron radiation datasets were collected on the macromolecular crystallog-
raphy beamlines I02 and I04, and the microfocus beamline I24 at Diamond Light
Source in Oxfordshire. The beamlines are based on U21 in vacuum undulators as
insertion devices, crystals were mounted on a 1 axis (φ) goniometer perpendicular
to the X-ray beam using Hampton cryoloops with a Rigaku ACTOR robot and
the Uni-puck system, allowing for quick screening of samples. The sample area at
I02 is shown as figure 16, and the specific details of each beamline are shown in
table 8.
Name Wavelength (A˚) Beam Size (FWHM, µm) Detector
I02 0.68–2.48 120Ö80 ADSC Q315r CCD
I04 0.73–1.91 120Ö80 ADSC Q315r CCD
I24 0.50–1.91 5–100 Pilatus 6M
Table 8: Beamline Details: I02 and I04 are standard macromolecular beamlines,
whilst I24 is a microfocus macromolecular beamline. Each beamline is based on a
U21 in-vacuum undulator as the insertion device. They are equipped with robotic
sample changers, and the sample stage is nitrogen-cooled to 100K as standard.
Crystals were tested by taking two frames at 90° from each other, to asses
the quality of diffraction. Those showing good levels of diffraction then had full
datasets collected, which were generally 180° φ scans with fine (generally 0.25°)
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Figure 16: Macromolecular crystallography beamline I02 at Diamond Light
Source: (A) 1-axis goniometer (φ); (B) Beamstop (retracted from experimental
position); (C) On-axis camera for crystal centering; (D) Cryostream; (E) Fluores-
cence scanner; (F) ADSC Q315 CCD image detector (retracted from experimental
position); (G) Robotic sample changer.
slicing. Where significant ice build up was seen on crystals, it was generally
found that returning them to the sample dewar, and remounting them on the
goniometer, using the robot was sufficient to remedy this.
5.10 Data Processing
In house datasets were indexed and integrated using the PROTEUM software
package from Bruker. Synchrotron datasets were first indexed using the HKL2000
package before integration and scaling using the XDS package.
Structure solution and refinement were undertaken using the CCP4 package of
programs [127]. Phasing was undertaken using the Phaser program and least-
squares refinement used the Refmac program [128] with Coot [129] used to visu-
alise and correct structures between successive rounds of refinements.
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6 Results – Serine Palmitoyltransferase from Tox-
oplasma gondii
6.1 Bioinformatics
Bioinformatic studies of TgSTP have identified the protein to be made up of three
domains. Transmembrane helix prediction using HMMTOP identified the first 47
amino acids to be a transmembrane domain. BLAST searches suggest that amino
acids 181 to 571 represent a conserved PLP-dependent aminotransferase domain,
showing significant homology across a broad range of species, in particular other
apicomplexans. Little is known about the intervening 134 amino acids, though
secondary structure prediction suggests that the domain is composed almost en-
tirely of α-helices. A diagram showing these domains can be seen as figure 17,
and a sequence alignment of the full length protein against a number of species
performed using ClustalW is included as appendix B.
Figure 17: A diagram of the proposed domain structure of TgSPT. The trans-
membrane helix is shown in red, the conserved aminotransferase domain is shown
in green, and the intervening 134 amino acids are shown in blue.
Whilst previous efforts had focused on the use of solubility tags to enhance
expression of constructs beginning with amino acid 47, it was decided to move
the study forwards by focussing on shorter constructs, aiming to find a minimal
functional domain. Initial efforts concentrated on the domain with the highest
homology to other aminotransferases, starting at amino acid 181. Whilst this
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domain proved to give abundant expression, in vivo functionality studies showed
that it was not functional. Therefore a number of further constructs were designed
based on areas predicted to be random coil between α-helices, starting at amino
acids 55, 69, 77, 90 107, 120, 132, 144, 159 and 177. Along with 47 and 181,
these were used for high-throughput screening at the Oxford Protein Production
Facility.
6.1.1 Comparative Modelling
The homology model of the conserved functional domain of TgSPT was calculated
using MODELLER [124]. The complete SPT sequence was used in the most
exhaustive search for similar sequences and resulted in a top hit with 29% sequence
identity with the crystal structure of SPT from Sphingobacterium multivorum
(PDB code: 3A2B) determined with the substrate L-serine covalently bound to
the co-factor PLP [130]. Other hits included the closely related SPT from other
sphingobacteria which showed the same overall fold albeit with lower sequence
identities. MODELLER then automatically calculated a model containing all
non-hydrogen atoms, and implemented comparative protein structure modeling
by satisfaction of spatial restraints and modelled loops in the protein structure de
novo [131, 132]. All models were then analysed and least-square superpositions
were performed with Coot [125]. The result is shown in figure 18, and shows that,
as might be expected, the protein is likely to be of a similar fold to the other
known SPT structures.
6.2 pETzt2 1
Previous work had suggested difficulties in extracting soluble protein [37]. For
this reason the vector pETzt2 1 was chosen (Figure 10). It includes a 10kDa
solubility enhancing and multi-histidine fusion tag linked to the protein by the
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Figure 18: The figure shows the overall fold of one SPT monomer with the PLP-
serine position taken from from 3A2B which clearly identifies the open binding
cleft. α-helix is shown in cyan; β-sheet in magenta; and random coil in puce. It is
important to note that although the overall position of the co-factor is very likely
to be similar the active site residue (Lys265) is not conserved in SPT from T.
gondii (see sequence alignment) . In solution the enzyme is likely to be a closely
inter linker homo-dimer as seen in other family members [130, 36].
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recognition site for the TEV protease allowing for later cleavage of the tag to
give the desired construct for crystallisation. The sequences of the primers used
are shown in Table 2. The sequence of the full construct, including the tag, is
included in appendix A. Masses, theoretical pI values for the tagged and cleaved
protein were calculated using the online ProtParam and are shown in Table 9
Tagged Protein Cleaved Protein
Number of Amino Acids 484 395
Molecular Weight\gmol−1 53777.3 43623.2
Theoretical pI 6.84 8.11
Table 9: Parameters calculated for TgSPT:181 from pETzt2 1 before and after
fusion tag cleavage.
6.2.1 Ovexpression
Figure 19: Expression and purification of tagged TgSPT181 from pETzt2 1 at
three temperatures: A 20; B 30; C 37. Key to lanes: 1 Total cell lysate; 2
Pre-incubation soluble; 3 Post-incubation soluble; 4-6 Wash fractions; 7 Purified
protein; 8 Total insoluble protein.
Initial Testing Initial expression tests were performed at 20, 30 and 37.
Small scale purification was undertaken for each sample which were then anal-
ysed by sodium docecylsulphate polyacrylamide gel electrophoresis (SDS PAGE)
(Figure 19). Good levels of expression were found at each temperature with the
highest levels of soluble protein at 30.
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6.2.2 Purification
Quantities (∼15mg) of tagged TgSPT have been isolated and purified as shown in
figure 20. Tag cleavage was attempted using TEV protease. As shown by the lack
of cleaved protein in lane 5 of the gel in Figure 20 this was unsuccessful, leaving
only tagged protein after overnight incubation at 4. It is believed that this is
due to steric inhibition, due to an insufficiently long linking region between the
cleavage site and the protein of interest. A positive control to test the activity of
the enzyme was performed by the expression of green fluorescent protein using an
identical system, from which the tag was successfully cleaved. This lends further
weight to the suggestion that it is a steric effect. However, whilst it is rather
difficult to imagine an alternative cause of the unsuccessful tag cleavage, it would
be rather difficult to prove this out-right, as this would require the re-cloning of
the construct with a longer linking region. Further difficulties were also had with
medium-term protein stability in solution, though these were resolved by changing
the buffer conditions for the protein.
Figure 20: Large scale expression and purification of tagged TgSPT181 from
pETzt2 1. Key to lanes: 1 Total cell lysate; 2 Initial pre-incubation soluble; 3 Ini-
tial post-incubation soluble; 4 Purified protein with TEV protease after overnight
incubation; 5 Unbound protein; 6 500mM imidazole column wash.
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6.2.3 Protein Buffers
A number of buffer conditions were screened across various values of pH with a
variety of different additives and buffers. An efficient optimum solubility screen
as outlined by Jancarik et al. [126] was carried out, though with only qualitative
evaluation of the levels of precipitation, as low protein concentration and heavy
precipitation made the use of dynamic light scattering unfeasible. This qualitative
evaluation was made by placing the drops of protein solution under a microscope,
and making a comparative judgement of in which condition there was the least
precipitated protein. pH was then further screened in stable conditions, and
the use of additives tested. Protein was found to be most stable in a 100mM
sodium/potassium phosphate buffer at pH 7.4 (made by adding 100mM sodium
phosphate to 100mM potassium phosphate until pH 7.5 is reached) with 1mM
dithiothreitol (DTT), 10% glycerol and 200mM NaCl, with DTT being the key
ingredient for maintaining solubility, suggesting that earlier problems had been
due to oxidation of the protein in solution.
6.2.4 PLP Binding
PLP has a strong yellow colour, and absorbs light strongly in the UV-blue region
of the electromagnetic spectrum. The OD at 400nm of purified TgSPT181 from
pETzt2 1a was measured before and after dialysis in buffer containing PLP, and
showed significant increases in absorption, suggesting that the PLP binding site
was intact in this heavily truncated construct.
6.3 pET24a
Previous work [37] had produced untagged constructs of full length TgSPT and
TgSPT47 in pET24a, which were shown to be functional in vivo by radio-isotope
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labelling, using the same protocols as have been used for the work outlined here.
An analogous construct for TgSPT181 has now been produced, and shown to
give high levels of soluble expression. The previous functionality study was then
repeated including this construct. The autoradiograph is shown as figure 21, and
clearly shows that no radiolabelled 3-dehydrosphinganine was produced by this
construct TgSPT181. Following this result, it was decided to return to tagged
longer constructs, with the aim of producing protein which was both soluble, and
functional.
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Figure 21: An autoradiograph of a TLC plate of lipids extracted from E. coli
cells containing two truncations of TgSPT as well as SpSPT as a positive control,
which were grown in radiolabelled serine. The dark spot clearly visible 2/3 of the
way up the plate on the first and fourth lanes is 3-dehydrosphinganine. Lanes
(from left to right) 1: TgSPT47; 2: TgSPT181; 3: Empty vector (pET24a); 4:
SpSPT.
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6.4 pGEX6.2
GST-tagged TgSPT47 was prepared using the vector pGEX6.2, and expressed
from a variety of cell lines expressed at both 16 and 30, and with two different
concentrations of IPTG (0.1 and 1mM). Crude soluble lysate from small-scale ex-
pression trials did not show obvious expression bands with SDS PAGE, so an anti-
GST Western Blot was performed (figure 22), which clearly shows the presence
of soluble GST-TgSPT47 fusion at around 80KDa from a number of conditions.
Figure 22: Western blot showing soluble expression of GST-TgSPT47 from
pGEX6.2 at c. 80kDa. Lanes 1–4 were expressed from BL21(DE3) and lanes
5–8 from Tuner. Lanes 9 and 10 contain GST as a positive control, the two bands
corresponding to roughly 25 and 50kDa; the monomer and homodimer.
Whilst little correlation was visible in general between the conditions, it was
clear that Tuner cells with higher concentrations of IPTG at 30 gave the most
consistently strong bands. Upon scaling up these conditions, the quantity of
soluble protein was seen to reduce greatly, perhaps due to a lengthened period
of expression causing overproduction of the protein, and subsequent production
of inclusion bodies in the cells. As with other constructs, whilst there seems to
be a theoretical possibility of producing soluble TgSPT47, in practice larger scale
cultures do not yield the expected result, and only vanishingly small quantities of
protein can be isolated.
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6.5 High-throughput Protocols
At least one successful construct was cloned for all but three of the 48 constructs
designed for high-throughput screening. This is shown by figure 23, which is a
agarose gel of the verification PCR carried out on the 96 plasmids prepared (two
for each construct). The gel was run from left to right in the image shown. As
constructs are all of a similar length, it is easy to see those which did not work, as
they are significantly shorter than those around them (such as lanes D1, E7 and
E12) suggesting that a construct shorter than the length intended was cloned,
or no strong band is visible at all (such as lane C1) suggesting that cloning was
completely unsuccessful.
Figure 23: An OPPF gel showing verification PCR. Lanes A1–12 and contain
DNA length standards. The verification PCR for first version of each construct
runs from J2 through to B6, in the order shown in tables 10 & 11, and the second
version from J7 through to B12.
These were then expressed by IPTG and autoinduction from B834 and Rosetta(DE3)pLysS.
Two gels showing protein purified from pOPINJ and pOPINS3C grown in Rosetta(DE3)pLysS,
by both autoinduction and IPTG induction are shown as figure 24. The proteins
of interest would be at around the level of the 75kDa molecular weight marker.
On the top gel (from autoinduction), whilst there is some limited expression seen
for a number of conditions, significant expression is only seen in the last four lanes.
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On the bottom gel (from IPTG induction), more expression is seen in lanes 10,
16, and 18-25. The drop in the vertical position of the band from lane 16 to 25 is
due to the steady decrease in the length of the cloned construct. The right hand
side of bottom gel shows the most successful set of conditions: pOPINS3C from
Rosetta(DE3)pLysS by IPTG induction. A full list of the conditions trialled, and
their success are shown in tables 10 & 11.
Figure 24: OPPF Gels: Expression from pOPINJ (lanes 2–13) and pOPINS3C
(lanes 14–25) in Rosetta(DE3)pLysS: autoinduction (top); 0.5mM IPTG induc-
tion (bottom). Lane 1 contains Precision Plus Protein Standard from BioRad.
Perhaps the most surprising result, given previous success with expression from
pGEX6.2 of GST tagged TgSPT47, is the distinct lack of success in the expression
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of GST tagged protein from pOPINJ. Another interesting result is that the N-
terminal His6 in pOPINF performed far better than the C-terminal His6 tag in
pOPINE, which are otherwise identical. This might suggest that the C-terminal of
the protein is not readily accessible from the surface, and that C-terminal tagging
has an effect on the correct folding, and therefore solubility, of the protein.
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Vector First AA Final AA Condition 1 Condition 2 Condition 3 Condition 4
pOPINF 48 571
pOPINF 55 571
pOPINF 69 571
pOPINF 77 571 (+)
pOPINF 90 571 (+) + (+)
pOPINF 107 571 (+)
pOPINF 120 571 (+) (+) +
pOPINF 123 571 + ++ (+) (+)
pOPINF 144 571 ++ (+)
pOPINF 159 571 + ++ + +++
pOPINF 177 571 +++ +++ +++ +++
pOPINF 181 571 +++ ++ +++ +
pOPINE 48 571
pOPINE 55 571
pOPINE 69 571
pOPINE 77 571 + (+) (+)
pOPINE 90 571 + (+) +
pOPINE 107 571
pOPINE 120 571 +
pOPINE 123 571 +
pOPINE 144 571 (+) ++
pOPINE 159 571 + ++
pOPINE 177 571 ++ ++ ++ +
pOPINE 181 571 ++ ++ +++ ++
Table 10: Success of preliminary expression and purification testing of constructs expressed at OPPF under various
conditions. Key to conditions: 1: Autoinduction, B834(DE3); 2: Autoinduction, Rosetta(DE3)LysS; 3: IPTG, B834(DE3);
4: IPTG, Rosetta(DE3)LysS. Key to symbols: (+): Some limited expression; +: Reasonable expression; ++: Strong
expression; and +++: Expression saturating Ni-NTA beads.
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Vector First AA Final AA Condition 1 Condition 2 Condition 3 Condition 4
pOPINJ 48 571
pOPINJ 55 571
pOPINJ 69 571
pOPINJ 77 571
pOPINJ 90 571
pOPINJ 107 571
pOPINJ 120 571 (+)
pOPINJ 123 571 (+)
pOPINJ 144 571 + ++ (+)
pOPINJ 159 571 +
pOPINJ 177 571
pOPINJ 181 571
pOPINS3C 48 571 (+)
pOPINS3C 55 571 (+) (+)
pOPINS3C 69 571 ++ +
pOPINS3C 77 571
pOPINS3C 90 571 + + ++
pOPINS3C 107 571 (+) +
pOPINS3C 120 571 (+) +
pOPINS3C 123 571 (+) (+) + ++
pOPINS3C 144 571 + +++ +++ +++
pOPINS3C 159 571 + +++ ++ +++
pOPINS3C 177 571 ++ +++ +++ +++
pOPINS3C 181 571 ++ ++ ++ ++
Table 11: Success of preliminary expression and purification testing of constructs expressed at OPPF under various
conditions. Key to conditions: 1: Autoinduction, B834(DE3); 2: Autoinduction, Rosetta(DE3)LysS; 3: IPTG, B834(DE3);
4: IPTG, Rosetta(DE3)LysS. Key to symbols: (+): Some limited expression; +: Reasonable expression; ++: Strong
expression; and +++: Expression saturating Ni-NTA beads.
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6.6 Summary
Whilst bioinformatics have suggested that a minimal functional domain exists
beginning at around amino acid 181, in vivo functionality testing using protein
expressed from E. coli have shown that this minimal construct does not show
functionality. A variety of constructs were tested, using both low-throughput
and high-throughput protocols. The best results were found to use short, sharp
expression with induction by IPTG from pET28a 3C-protease-cleavable His6 and
a SUMO tag.
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7 Results – Small Heat Shock Proteins from Methanococ-
cus jannaschii
7.1 Bioinformatics
Bioinformatics and construct design were undertaken by Andrew Landsbury in
Durham’s Department of Biological and Biomedical Sciences. An alignment of
MjHSP16.5 with human αB-crystallin performed with ClustalW is included as
appendix G. Two C-terminal truncation mutants, 3FR and 4FR, designed to
mimic the myopathy-causing Q151X truncation in αB-crystallin., were produced.
The extent of the truncation in 4FR is shown in figure 25, and their sequences
included as appendix F. A third mutant, R107G, was designed to mimic the
myopathy causing R120G mutation in αB-crystallin.
Figure 25: The interface between two dimers of HSP. The purple section shows
the extent of the 4FR truncation, on the red dimer.
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7.2 Protein Production
Native and truncated proteins were expressed and purified by Andrew Landsbury
in the Department of Biological and Biomedical Sciences, Durham University
following the procedures laid out by Kim et al. [81]. SDS PAGE was then used to
asses the purity of samples (an example is shown as figure 26), and LC FTICR MS
was then used to verify the identity of the protein by its exact mass (an example
used to identify that R107G had been correctly mutated is shown as figure 27).
Figure 26: An SDS PAGE gel showing the purity of samples of native MjHSP
used for crystallisation.
7.3 Native Protein
Positive results were observed in two drops and selected for further screening:
Conditions 34 (35% (v/v) MPD, imidazole pH8.0, 0.2M MgCl2) and 37 (40%
(v/v) PEG-300, MES pH6.5) of the Emerald BioSystems Cryo I+II screen. A
good yield of crystals was found in the condition 37 optimisation, though it was
not possible to reproduce the crystal growth from condition 34.
Further trays were also set up using the conditions outlined by Kim et al. and
incubated at both 4 and 18, as shown in table 7. These yielded a significant
number of good sized crystals which grew overnight in all drops at 18, though
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Figure 27: The deconvoluted mass spectrum used to verify that the R107G mu-
tation had been successful. The mass peak at 20059.4gmol−1 corresponds well to
the expected mass of 20059gmol−1.
far fewer crystals were seen to grow at 4, and those which did required weeks to
grow. Diffraction was observed to approximately 6.5A˚ for the crystals grown in
screen condition 37. No further testing was possible due to technical difficulties
with the diffractometer.
Further crystals were grown, and tested on beamline I02 at Diamond Light
Source. Diffraction was seen to ∼2.45A˚ for the crystals grown from the published
conditions and, less successfully, to 2.8A˚ for the crystals from the condition 37
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Protein Date Beamline Resolution Frames φ Slicing φ Range
MjHSP 15-Apr-2009 I02 2.45A˚ 360 0.5° 180°
3FR 15-Jul-2009 Durham 7.40A˚ 623 0.1° 62.3°
3FR 27-Sep-2009 I02 3.85A˚ 180 0.5° 90°
3FR 27-Sep-2009 I02 3.95A˚ 180 0.25° 45°
3FR 23-Feb-2010 I24 3.35A˚ 300 0.4° 120°
3FR 23-Feb-2010 I24 3.20A˚ 300 0.4° 120°
4FR 09-Jun-2009 Durham 7.80A˚ 605 0.1° 60.5°
4FR 27-Sep-2009 I02 3.45A˚ 180 0.5° 90°
R107G 23-Feb-2010 I24 3.20A˚ 225 0.4° 90°
R107G 23-Feb-2010 I24 3.35A˚ 225 0.4° 90°
R107G 23-Feb-2010 I24 3.15A˚ 225 0.4° 90°
R107G 17-Dec-2010 I04 3.25A˚ 180 0.25° 45°
R107G 22-Jan-2011 I04 2.60A˚ 520 0.35° 182°
R107G 22-Jan-2011 I04 3.00A˚ 182 1° 182°
Table 12: Full datasets collected on crystals wild-type MjHSP16.5, R107G, and
the truncation mutants.
optimisation. A 180° φ scan with a slicing of 0.5° was collected at 1 second per
frame. A typical frame, showing diffraction to ∼2.5A˚ is shown in figure 28.
The unit cell was found to be the same as that for the published structure (Space
group: R3, a = b = 171.58A˚, c = 102.22A˚). Further data collection statistics are
shown in table 13. It should be noted, that whilst the extension in resolution
against the published structure does not sound all too profound, it represents the
collection of 50% more data; 33,049 reflections as opposed to the 22,008 recorded
for the structure published by Kim et al..
The data were indexed and integrated using HKL2000 and XDS. Structure
solution was then undertaken using Phaser by molecular replacement with the
published structure (PDB code: 1SHS). A number of different levels of NCS
restraint including differing restraints for the main chain and side chain atoms
were tested, and in both cases the tightest level of restraint was found to give the
best results, with the lowest values of R and Rfree. A representative section of the
electron density is shown in figure 29, giving an idea of the extent to which the
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Figure 28: A typical frame of diffraction collected on crystals of MjHSP16.5 at
Diamond Light Source showing diffraction to ∼2.5A˚ resolution.
secondary structure can be traced through the density. A number of side chains
were found to be disordered and treated as having an occupancy of zero.
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Table 13: Comparative data collection and refinement statistics for MjHSP.
Published Structure Higher Resolution
Data Collection Statistics
Resolution\A˚ 30.0–2.9 85–2.5
Completeness 99.7% 98.6%
Rsym 0.037 0.034
Refinement Statistics
Unique reflections (F > 2σ) 22,008 33,049
Completeness (F > 2σ) 80.6% 85.1%
R factor 0.216 0.252
Rfree 0.251 0.272
Bond-length deviation\A˚ 0.023 0.017
Bond-angle deviation 1.505° 1.65°
Figure 29: Representative region of the 2Fo–Fc electron density map based on the
redetermined structure contoured at 1.22σ.
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Figure 30: Cartoon depiction of the higher resolution structure of the icositetramer
of MjHSP, looking down a four-fold axis. α-helix is shown in red; β-sheet in yellow;
and random coil in green.
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7.4 Truncated Proteins
A crystallisation screen was set up for truncate 3FR under the published condi-
tions for the full length protein. High levels of precipitation were noted, though
after a week of incubation at 18 small, 0.05 × 0.02 × 0.01mm, crystals were
seen to form in all drops. Further screens were set up, and larger crystals suit-
able for diffraction studies were obtained. Initial testing in house showed only
limited diffraction to 7–8A˚. More crystals were grown, and taken to DLS, where
diffraction was observed to 3.85A˚. Initial indexing suggests the crystal to have a
tetragonal unit cell of ∼125×125×180A˚.
Further rounds of optimisation were undertaken, and Andrew Landsbury im-
proved the purification protocol to give higher purity protein, though significant
increases in concentration were not possible, due to heavy precipitation on spin
concentration. This yielded increased size crystals, though nowhere near the size
of those obtained for the wild type protein, at around 0.15×0.05×0.05mm. These
were taken to the microfocus beamline I24 at Diamond Light Source, where diffrac-
tion to 3.20A˚ was observed, though at the time of writing it has not been possible
to extend this resolution further. Details of all full datasets collected are included
in table 12.
High levels of non-crystallographic symmetry are shown by the auto-rotation
function shown in figure 31. This function is created by taking one Patterson
synthesis and rotating it by a set angle, each peak in the function representing
the extent of coincidence between the rotated and original functions at the relevant
degree of rotation. For example, in the function shown for Chi=120, the four peaks
each represent a separate 3-fold axis of non-crystallographic symmetry. This high
level of non-crystallographic symmetry has also proved a significant hindrance in
structure solution using molecular replacement, as it creates multiple solutions to
the equations, giving uncertainty in the result. A number of different models based
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on the wild type structure were tried for molecular replacement aiming to find a
model which represents the contents of the asymmetric unit, but without success.
It is however clear from the high level of non-crystallographic symmetry present
that the functional unit of an octahedral icositetramer must be maintained, and
therefore that only crystal packing is significantly affected by the truncation.
As with truncate 3FR, a crystallisation screen was set up for truncate 3FR
under the published conditions for the full length protein. Again high levels of
precipitation were noted, as well as the growth of small crystals. Further to this
a number of slightly larger crystals , 0.1×0.05×0.02mm, grew in one drop at the
highest concentration of precipitant. These were tested on the rotating anode and
diffraction was observed to ∼6A˚. Figure 32 shows one such crystal mounted in a
cryoloop along side a frame showing the extent and quality of its diffraction. A 60°
φ scan with a fine slicing of 0.1° was collected at 120s per frame. Initial indexing
suggested the crystal may have a tetragonal unit cell of ∼125×125×180A˚, as with
3FR.
These results were confirmed with larger crystals of 4FR, which were tested at
Diamond Light Source. Given the strong similarities seen between the datasets
for 3FR and 4FR, it was decided to discontinue study of 4FR, and focus efforts
on obtaining better crystals of 3FR.
7.5 Point Mutation R107G
As with other mutants, conditions were screened around those published for the
wild type protein. Improvement in crystal quality through successive rounds of
improving the purity of the protein, and optimisation of crystallisation conditions
can be seen in figure 33. Initially arrays of very small crystals were grown. It
was then possible to improve these to small single crystals, and then to large
single crystals, of up to 1mm in their longest dimension. The main factor driving
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Figure 31: Auto-rotation function calculated for a 3FR dataset, showing the high
level of non-crystallographic symmetry present [133]. 8 peaks can be seen corre-
sponding to 2-fold NCS, 4 corresponding to 4-fold NCS, and 4 corresponding to
3-fold NCS.
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Figure 32: A crystal of mutant 4FR mounted in a 0.2mm cryoloop and a frame
showing its diffraction (0.1° φ scan, 120s, weak diffraction visible to ∼6A˚).
forwards improvements in crystal quality was once again the improvement in the
purity and concentration of the protein solution. Concentrations of up to 40mg/ml
were used, though it was generally found that 20–30mg/ml yielded the best results.
Figure 34 shows a very large crystal of R107G mounted in a LithoLoop from
Molecular Dimensions on beamline I24 at Diamond Light Source. Due to the size
of the crystal, and relatively poor back-lighting, it is not possible to see the crystal
fully. However, interestingly, another factor which compounds this is the general
opacity of the crystal. This seems to have been due to the crystals growing around
the amorphous precipitate, and yet does not seem to have had a particularly
adverse effect on the general quality of diffraction. Indeed the strongest trend in
the quality of diffraction was a direct correlation between the resolution obtained
and the size of the crystals. It can only be assumed that the factors allowing such
large crystals to grow, also increase the general intrinsic quality of diffraction.
After many rounds of optimisation, a 2.85A˚ dataset was collected on beamline
I24 at Diamond Light Source (details of all full datasets collected are included
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Figure 33: Various images of hanging drops containing crystals of R107G, showing
progressive improvements in the quality of crystals. The largest single crystals
are of the order of 1mm along their longest axis.
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Figure 34: A large crystal of R107G mounted on the microfocus beamline I24 at
DLS. The small red square shows roughly the position and the size of the beam
used for data collection.
in table 12). The data were then indexed and integrated using HKL2000, and
phasing was undertaken using Phaser, using the published wild type structure as
a model. the unit cell was found to be near identical to that for the wild type
structure (Space group: R3, a = b = 173.60A˚, c = 103.00A˚). The structure of
R107G imposed upon the wild type structure is shown in figure 35, from which
the broad similarities between the two structures are clear. Furthermore, the
calculated route mean squared deviation (rmsd) on the Cα atoms between the
wild type structure and R107G, for each chain are between 0.3 and 0.4A˚, well
within the standard experimental error, more conclusively demonstrating that
there is no significant difference between the two structures.
For phasing, the arginine was included in the model, and therefore a significant
region of negative electron density can be seen in the density map, as shown in fig-
ure 36. The arginine was then replaced with glycine, and the significantly cleaner
electron density after refinement is shown in figure 37. The crystallographic refine-
ment therefore quite unambiguously shows that the arginine has been mutated to
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Figure 35: A superimposition of the contents asymmetric unit cells of wild type
HSP (blue) and R107G (red), showing the broad similarity between the two struc-
tures.
glycine, even at this relatively modest resolution. Statistics from data collection
and refinement are included as table 14.
7.6 Summary
For the wild-type protein, the crystal structure has been re-determined at a sig-
nificantly increased resolution of 2.45A˚, representing and increase of 50% in the
number of reflections collected. This increased resolution was obtained from crys-
tals grown in the same conditions as those published by the original authors,
and most likely represents improvements in purification protocols, coupled with
significant improvements in synchrotron X-ray production, diffraction and data
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Figure 36: Representative region of the experimental electron density map for
R107G contoured at 1.0σ, before refinement. As expected, there is a clear dis-
agreement between the experimental electron density map and the model at po-
sition 107, as the model still contained the side chain for arginine.
collection technologies.
For the point mutation R107G, the crystal structure has been determined, and it
has been found that this mutation causes no significant effect observable by X-ray
crystallography, though differing solution-state behaviours were observed. The
two truncation mutations have proved less accessible by X-ray crystallographic
techniques, due in part to their greater instability in solution, though the limited
data collection that has been possible suggests that this mutation causes a more
significant effect in crystallographic terms, though it still does not appear to have
significant effect on the quaternary structure of the protein.
81
Figure 37: Representative region of the experimental electron density map for
R107G contoured at 1.0σ, following refinement with position 107 as a glycine.
Table 14: Data collection and refinement statistics for R107G.
Data Collection Statistics
Resolution/rA 49.22–2.85
Completeness 99.7%
Rsym 0.035
Refinement Statistics
Unique reflections (F > 2σ) 26,318
Completeness (F > 2σ) 97.4%
R factor 0.1803
Rfree 0.2701
Bond-length deviation/rA 0.011
Bond-angle deviation 1.66°
Mean B Value/A˚2 105.14
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8 Conclusions & Future Work
8.1 Toxoplasma gondii Serine Palmitoyltransferase
Initial efforts focused on isolating stable quantities of the tagged 181-truncate,
as was expected from homology with the other published structures discussed.
However, functionality studies demonstrated that this minimal construct did not
have serine palmitoyltransferase activity, and a return was therefore made to
much longer constructs, in the hope of isolating protein which was both soluble,
and functional. It is surprising given the high levels of homology seen with the
published structures that this domain was not functional, and indeed it leads one
to believe that the acids between 47 and 181 do have some role in the function of
the protein. This move to the other extreme, however, brought back the problems
which had previously been experienced in trying to obtain significant quantities of
constructs with limited solubility, and whilst limited soluble expression was seen
in small scale trials for a construct beginning at amino acid 47 with a GST tag
from the pGEX system, it was very limited, and proved not to be reproducible
on a larger scale.
It is therefore hoped that the results showing significant quantities of soluble
expression from a number of the intermediate constructs produced at the Oxford
Protein Production Facility may offer a middle ground for moving forwards. These
constructs offer such a tantalising step towards crystallisation trials, and thence to,
one might hope, diffraction, and a crystal structure, particularly of a construct
larger than just the proposed functional domain. This will structure will then
finally answer the questions both about the form of the active site and functional
unit, and the purpose of the amino acids before acid 181. It is, though, important
to remind ourselves of the note of caution that drew us away from the abundant
soluble expression of the minimal constructs, and before progressing too rapidly
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with crystallisation trials, to ensure that the soluble protein is also functional.
8.1.1 Functionality Studies
The protocol used for testing the functionality of constructs using [14C]-serine is
relatively difficult, and expensive to perform, given the involvement of radioactive
material. It is also to a large extent qualitative. Moving forward, it would be valu-
able to be able to use a more simple in vivo protocol, which might also offer more
quantitative, and conclusive results, particularly given future hopes of producing,
and therefore testing, new inhibitors. I therefore suggest the use of the protocol
included as appendix H, which avoids the use of radio-isotopes, and instead uses
mass spectrometry, giving much more conclusive indications of the presence of the
desired species in cell lipid extracts. Using the set of constructs produced at the
OPPF this will show at which extent of truncation it is that functionality is lost,
again giving further information about the purpose of the domain between amino
acids 47 and 181, and informing for which constructs crystallisation ought to be
pursued, as it is clear that a crystal structure of a functional protein is far more
valuable than one which has no function.
Moving from in vivo to in vitro Functionality Testing This protocol is,
however, still flawed, in that it cannot show for certain that the function of the
construct is not reliant upon the host machinery in E. coli to in some way sup-
plement its activity. Looking further forward it should therefore be desirable to
perform in vitro functionality studies. Yard et al. use a [14C]-serine-based in
vitro functionality test [36], and there should be no great difficulty in replacing
[14C]-serine with normal serine, and using mass spectrometry instead of TLC and
autoradiography in order to detect ketodihydrosphingosine, giving an easy route
to in vitro functionality testing, where soluble protein is available.
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8.1.2 Crystallographic Prospects
The first step in moving forwards to crystallographic studies will be scaling up
the 2.5ml high-throughput expression trials to the litre scale. This work should
focus on the constructs expressed from pOPINS3C in Rosetta(DE3)pLysS with
induction by IPTG. Whilst the most obvious target is the TgSPT144, being the
longest construct with very high soluble protein expression, there is certainly some
value in also considering the expression of TgSPT90 from this same system. Not
only does it also display a good level of expression, but it is also significantly
longer, offering the potential to elucidate the nature of the domain between the
transmembrane helix and the conserved aminotransferase domain; perhaps that
which is most interesting in TgSPT.
8.2 Methanococcus jannaschii Small Heat Shock Protein
The redetermination of the structure of HSP16.5 from M. jannaschii at higher
resolution has laid the ground work for a series of structural studies on mutants
designed to mimic particular types of human disease. The first of these to be solved
is that of R107G. Whilst there is only limited difference between this structure,
and that of the wild type protein, this important result does begin to give us
an insight into the relationship between MjHSP16.5 and human αB-crystallin. It
leads us to ask the question why a residue with such key effect in αB-crystallin,
and which is so highly conserved across all three kingdoms of life, has such limited
observable effect observable by crystallographic studies in MjHSP16.5.
The crystal structure clearly shows that the effects of the mutation do not come
down to a simple conformational change. It is perhaps possible that it leads only
to a change of conformation in solution, an effect which would not be visible in
our structure due to crystal lattice constraints. It is also possible that the effect
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could come down to a change in dynamic behaviour, which again would not be
visible in our crystal structure. The final possibility that I would propose is that,
as many other HSPs show many multimeric states in solution, so the R107G
mutation could cause changes in this behaviour, something which again would
not be visible in the crystal structure.
To further study this mutation, NMR is out of the question for considering the
dynamic effects, given the large size of the functional unit. I would therefore
suggest that computational methods such as modelling the system as an elastic
network model may yield results in further understanding this system. For con-
sidering the less dynamic solution-state effects, particularly the question of what
effect the mutation has on the presence of different multimeric states in solution,
I would propose the use of a combination of small angle X-ray scattering and
electron microscopy, if the differences in states are sufficient to be distinguished
on the electron microscopy grid. Both techniques are able to identify the size of
particles, X-ray scattering giving information about the distribution of particle
sizes in solution, avoiding the difficulties encountered with the frozen crystallo-
graphic state, and electron microscopy being able to give more information about
the shape individual discrete states observed. In practice, however, it is only
the combination structural and other biophysical techniques which can solve this
problem.
The way forward, however, is clear for the truncation mutants. Datasets have
been collected for a different set of mutants, 3FR and 4FR, which come tantalis-
ingly close to the 3A˚ mark. Further improvements in sample quality, coupled with
successive improvements in crystallisation conditions are surely all that is neces-
sary to break the resolution barrier, and gain valuable information about how of
the C-terminal truncation has affected the surface functionality of MjHSP16.5.
This will be particularly important in terms of which residues are unmasked, how
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this in turn affects such properties as the hydrophobicity, and how this in turn
might affect the protein’s properties as a chaperone, and its likeliness to aggregate
in cellular conditions. There does, though, still exist the barrier present in the
effects of non-crystallographic symmetry on this structure solution, as discussed
in section 7.4, which should not be taken lightly. Given the rarity of such systems,
the current suite of programs is not well equipped to deal with such situations,
and significant work may prove necessary to overcome this hurdle. One possible
solution lies in finding the complete assymetric unit contents, and using that as
the search model, thus by-passing the difficulties with the current suite of com-
puter programs. This technique was described by Tong in 2001 [134], but given
the complexity, and high levels of non-crystallographic symmetry present in this
system, it will be by no means straight-forward.
8.3 Overall Summary
Through the auspices of studies into two separate protein systems, the process of
protein crystallography has been discussed from cradle to grave. In the first case,
the serine palmitoylransfearse from T. gondii, we have looked at the early stages of
this process, leading up to the isolation of significant amounts of protein in prepa-
ration for crystallographic trials. In this we have been successful, demonstrating
expression from a number of truncates, and finding that the short, sharp expres-
sion of proteins using a SUMO tag and IPTG induction is most successful. We
have also gained insights into the domain structure of TgSTP, using both bioinfor-
matic techniques, and in vivo isotope labelling studies. We leave this system in a
position from which it can immediately move forward to crystallisation trials, and
with improved protocols for functionality testing, which offer an easier, quicker,
cheaper and more quantitative method for evaluating protein functionality, which
will surely prove valuable in any search for active inhibitors.
87
In the second case we have looked at the small Heat Shock Protein 16.5 from M.
jannaschii, and three mutants thereof as analogues for disease-causing mutations
in human αB-crystallin, starting from the stage of having isolated pure protein,
and working through the stages of crystallisation, data collection and structure
solution. For the wild-type protein, the crystal structure has been re-determined
at a significantly increased resolution of 2.45A˚, representing and increase of 50%
in the number of reflections collected. This increased resolution was obtained from
crystals grown in the same conditions as those published by the original authors,
and most likely represents improvements in purification protocols, coupled with
significant improvements in synchrotron X-ray production, diffraction and data
collection technologies. Whilst this has not extended the knowledge of the pro-
tein, it has improved the certainty of our models, and in a system where surface
functionality is key, this is valuable knowledge.
For the point mutation R107G, the crystal structure has been determined, and
it has been found that this mutation causes no significant effect observable by
X-ray crystallography, though differing solution-state behaviours were observed.
Whilst this represents the end of crystallographic studies for this mutation, it
leaves many questions unanswered, with the door open to further studies into
its mode of action. The two truncation mutations have proved less accessible
by X-ray crystallographic techniques, due in part to their greater instability in
solution, though the limited data collection that has been possible suggests that
this mutation causes a more significant effect in crystallographic terms, though it
still does not appear to have significant effect on the quaternary structure of the
protein. The way forward for these systems is therefore clear, we need to pursue
both the quality of crystals, improving the resolution, whilst looking at ways to
overcome the difficulties had in solving the structure due to non-crystallographic
symmetry, two ends which can be pursued side-by-side.
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A Serine Palmitoyltransferase Sequences
A.1 Full length protein:
MASGATYFTRGTGSPFLGAGVEWASNIDLFLCAFLSASVLGILLAFFNDEVSWGSLRWSW
IATQLLPITPCSSHAVYKDVETALAKAARNKAGSKRALEEFLAALQDGTVMVLLSKWSAR
GFERLAFYWQALKIKYTAQSRRQFFYQMQKVQLKLEIKPGETEMQSYNDAKRYMKSRDLW
PFAYEVSNVKDTQVICEGVRAYPMSSYSYLDFVREPLQEAALAAGRTWSTGNHGARMLGG
NMRILRDLEKMVGRFFGREDSLLCATGFLATMSSICAVAKEGDLIVGDNRLHASLRSGMK
LSGAKEMLFRHNNWHHLQQTLAKHRRKYKNCWIVIESVYSMDGDIADLPVVRRLADQYNC
RILLDEAHGLGVLGKTGRGLEEHFNMPGAADVIVGTFSKSIGGVGGYITGDNDLVEFLDF
HAPGSVFSAPLTAYSAGGAMMAFELMQGEQSWRIAKAQENAKYLRHALQTGLGLWPKDYP
AERKFELEGVACTTVIPVVFPHDGDRVFRVTQAMLKRGWMVAAAAYPACPLNRPRIRVTA
TAAYNQKMMDEFVKSLVEVTVECPPTDMLR
A.2 Fusion protein 181 from pETzt2 1
MKHHHHHHPMKQHDEAVDNKFNKEQQNAFYEILHLPNLNEEQRNAFIQSLKDDPSQSANL
LAEAKKLNDAQAPKVDAGSGSGSENLYFQGAMAPFAYEVSNVKDTQVICEGVRAYPMSSY
SYLDFVREPLVQEAALAAGRTWSTGNHGARMLGGNMRILRDLEKMVGRFFGREDSLLCAT
GFLATMSSICAVAKEGDLIVGDNRLHASLRSGMKLSGAKEMLFRHNNWHHLQQTLAKHRR
KYKNCWIVIESVYSMDGDIADLPVVRRLADQYNCRILLDEAHGLGVLGKTGRGLEEHFNM
PGAADVIVGTFSKSIGGVGGYITGDNDLVEFLDFHAPGSVFSAPLTAYSAGGAMMAFELM
QGEQSWRIAKAQENAKYLRHALQTGLGLWPKDYPAERKFELEGVACTTVIPVVFPHDGDR
VFRVTQAMLKRGWMVAAAAYPACPLNRPRIRVTATAAYNQKMMDEFVKSLVEVTVECPPT
DMLR
Section Colour
His tag Green
ZTag2 Blue
TEV Recognition Site Red
181 Truncate Orange
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B Serine Palmitoyltransferase Alignment
Abbreviation Enzyme
SpSPT Sphingomonas paucimobilis Serine Palmitoyltransferase
EcAKCL Escherichia coli 2-Amino-3-ketobutyrate CoA Ligase
RcALS Rhodobacter capsulatis 5-Aminolaevulinate Synthetase
TgSPT Toxoplasma gondii Serine Palmitoyltransferase
Amino Acids Colour Characteristics
AVFPMILW Red Small (Small & Hydrophobic (Incl. Aromatic -Y))
DE Blue Acidic
RK Magenta Basic
STYHCNGQ Green Hydroxyl + Amine + Basic - Q
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C Serine Palmitoyltransferase Homology Model
Alignment
This sequence alignment was performed with ClustalX using the standard colour-
coding.
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D Serine Palmitoyltransferase Secondary Struc-
ture Prediction
MASGATYFTRGTGSPFLGAGVEWASNIDLFLCAFLSASVLGILLAFFNDEVSWGSLRWSW
CCCCCEEEECCCCCCHCCCHHHHHHHHHHHHHHHHHHHHHHHHHHHHCCCCCCCCHCHHH
IATQLLPITPCSSHAVYKDVETALAKAARNKAGSKRALEEFLAALQDGTVMVLLSKWSAR
HHHHHCCCCCCCHHHHCHHHHHHHHHHHHCHHHHHHHHHHHHHHHHCCCHHHHHHHHHHH
GFERLAFYWQALKIKYTAQSRRQFFYQMQKVQLKLEIKPGETEMQSYNDAKRYMKSRDLW
HHHHHHHHHHHHHHHHHHHHHHHCCHHHHHHHHHHCCCCHHHHHHHHHHHHHHHHHCCCC
PFAYEVSNVKDTQVICEGVRAYPMSSYSYLDFVREPLVQEAALAAGRTWSTGNHGARMLG
CCCEEECCCCCCEEEECCCEEEECCCCCHCCCCCCHHHHHHHHHHHHHHCCCCCHHHHHC
GNMRILRDLEKMVGRFFGREDSLLCATGFLATMSSICAVAKEGDLIVGDNRLHASLRSGM
CCHHHHHHHHHHHHHHCCCHHEEEECCCHHHHHHHHHHHCCCCCEEEECHHHHHHHHHHH
KLSGAKEMLFRHNNWHHLQQTLAKHRRKYKNCWIVIESVYSMDGDIADLPVVRRLADQYN
HHCCCEEEEECCCCHHHHHHHHHHHHHHCCCEEEEEECEEECCCCCCCHHHHHHHHHHCC
CRILLDEAHGLGVLGKTGRGLEEHFNMPGAADVIVGTFSKSIGGVGGYITGDNDLVEFLD
CEEEEEHHCCCCEECCCCCCHHHHCCCCCCCEEEEEEHHHHCCCCCCEEECCHHHHHHHH
FHAPGSVFSAPLTAYSAGGAMMAFELMQGEQSWRIAKAQENAKYLRHALQTGLGLWPKDY
HHCCCCEECCCCCHHCHHHHHHHHHHHCCCCHHHHHHHHHHHHHHHHHHHHCCCCCCCCC
PAERKFELEGVACTTVIPVVFPHDGDRVFRVTQAMLKRGWMVAAAAYPACPLNRPRIRVT
CCHCCCCCCCCCCCCCEEEEECCCHHHHHHHHHHHHHCCCEEEEECCCCCCCCCCEEEEE
ATAAYNQKMMDEFVKSLVEVTVECPPTDMLR
ECCCCCHHHHHHHHHHHHHHHHHCCCCCCCC
Letter Secondary Structure Feature
C Random Coil
H β Sheet
E α Helix
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E αB-Crystallin Sequences
E.1 Wild Type Sequence
MDIAIHHPWIRRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLRAPSW
FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISREFHR
KYRIPADVDPLTITSSLSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK
E.2 Crystal Structure Sequence
GAMEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISREFHRKYR
IPADVDPLTITSSLSSDGVLTVNGPRKQVSGPER
Truncation
MDIAIHHPWIRRPFFPFHSPSRLFDQFFGEHLLESDLFPTSTSLSPFYLRPPSFLRAPSW
FDTGLSEMRLEKDRFSVNLDVKHFSPEELKVKVLGDVIEVHGKHEERQDEHGFISREFHR
KYRIPADVDPLTITSSLSSDGVLTVNGPRKQVSGPERTIPITREEKPAVTAAPKK
Section Colour
Residues not present in the crystal structure Red
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F Heat Shock Protein 16.5 Sequences
F.1 Wild Type Sequence
MFGRDPFDSLFERMFKEFFATPMTGTTMIQSSTGIQISGKGFMPISIIEGDQHIKVIAWL
PGVNKEDIILNAVGDTLEIRAKRSPLMITESERIIYSEIPEEEEIYRTIKLPATVKEENA
SAKFENGVLSVILPKAESSIKKGINIE
F.2 Truncation Mutations 3FR and 4FR
MFGRDPFDSLFERMFKEFFATPMTGTTMIQSSTGIQISGKGFMPISIIEGDQHIKVIAWL
PGVNKEDIILNAVGDTLEIRAKRSPLMITESERIIYSEIPEEEEIYRTIKLPATVKEENA
SAKFENGVLSVILPKAESSIKKGINIE
Section Colour
Extent of 3FR Deletion Red
Extent of 4FR Deletion Blue
F.3 Point Mutation R107G
MFGRDPFDSLFERMFKEFFATPMTGTTMIQSSTGIQISGKGFMPISIIEGDQHIKVIAWL
PGVNKEDIILNAVGDTLEIRAKRSPLMITESERIIYSEIPEEEEIYGTIKLPATVKEENA
SAKFENGVLSVILPKAESSIKKGINIE
Section Colour
Site of Arginine to Glycine Mutation Green
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G αB-Crystallin Sequence Alignment
Abbreviation Enzyme
HsaBC Homo sapiens αB-Crystallin
MjHSP Methanococcus jannaschii Small Heat Shock Protein 16.5
Amino Acids Colour Characteristics
AVFPMILW Red Small (Small & Hydrophobic (Incl. Aromatic -Y))
DE Blue Acidic
RK Magenta Basic
STYHCNGQ Green Hydroxyl + Amine + Basic - Q
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H In vivo Functionality Study Protocol Using Mass
Spectrometry
1. Transform chemically competent E. coli (Rosetta, pLysS), plating out, and
incubating overnight at 37;
2. Pick one colony, and inoculate a 2ml overnight culture (LB broth in a 15ml
falcon tube, with the correct antibiotics), incubate at 37 with shaking at
120 rpm;
3. Inoculate a 15ml culture (Power Broth, in a 50ml falcon tube, with the
correct antibiotics) with 150µl of the overnight culture;
4. Grow with shaking at 120 rpm at 37 until the OD 600nm reaches 0.6 and
induce with IPTG to a final concentration of 1mM;
5. Incubate for 3 hours, then harvest the cells by centrifugation at 6000Ög for
10 minutes;
6. Decant the supernatant and resuspend the pellet in 1ml 10:10:3 chloroform:
methanol:water (HPLC grade reagents), reserving a small amount of the
pellet for analysis by SDS-PAGE to check expression levels [N.B. From this
point forward, all contact with plastic ware should be avoided where possi-
ble];
7. Vortex the resuspended materials with a small quantity of glass beads for 5
minutes to ensure cell lysis;
8. Spin the cell material at 14,000 for 10 minutes;
9. Using a fine-tipped Pasteur pipette carefully extract the lower organic phase,
containing the desired lipids.
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Colloquia & Conferences
Colloquia
14th October 2008 Prof Tom McLeish, University of Durham
“Listening to Noise in Biological Physics from Protein Dynamics to Evolutionary
Landscapes”
15th October 2008 Prof Rob Field, John Innes Centre
“From biofuels to homeland security: challenges for chemistry and chemical biol-
ogy”
22nd October 2008 Prof Mike Ward, University of Sheffield
“Polyhedral coordination cages”
11th November 2008 Prof Rick Lewis, University of Newcastle upon Tyne
“Molecular architecture of the stressosome, a signal integration and transduction
hub”
12th November 2008 Prof Alan Bond, Monash University, Australia
“Electrochemistry and photochemistry in ionic liquids: separating fact from fic-
tion”
25th November 2008 Dr Peter Urwin, University of Leeds
“Pests, Trials and Tribulations”
18th January 2009 Prof Mark Weller, Southampton University
“From Greenland to Grenoble; The Structural Chemistry of New Frameworks and
All Sorts of Hydrogen Compounds”
21st January 2009 Dr Fred Manby, University of Bristol
“Electronic structure theory for solids, liquids and enzymes”
28th October 2009 Prof Bill Clegg, University of Newcastle
“Bringing the power of syncrotron radiation to the chemical community”
5th March 2009 Prof Jason Micklefield, University of Manchester
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“Synthetic Biology: From Nucleic acid Redesign to Engineering Biosynthetic Path-
ways”
6th May 2009 Prof Erick M. Carreira, ETH Zurich, Switzerland
“Discovery and Surprises with Small Molecules”
7th May 2009 Prof Wilson Poon, University of Edinburgh
“It’s a Bug’s Life: A Survey of The Physics of Bacteria”
12th May 2009 Professor Gerard Meijer, Fritz-Haber Institute of the MPG,
Berlin
“Cold Molecules”
12th May 2009 Dr Sean Munro, Cambridge University
“How to find the Golgi apparatus - GTPases, coiled-coil proteins and transmem-
brane domains”
Conferences
16th December 2008 Newcastle University
British Crystallographic Association Biological Structures Group Winter Meeting
3rd – 5th May 2009 University of Nottingham
CCP4 Study Weekend: “Experimental Phasing and Radiation Damage”
28th March – 6th April 2009 Trevelyan College, University of Durham
British Crystallographic Association Chemical Crystallography Group Intensive
Teaching School in X-ray Structure Analysis
21st – 23rd April 2009 University of Loughborough
British Crystallographic Association Spring Meeting: “Dynamic Crystallography”
Presented poster: “Towards the Crystal Structure of the Serine Palmitoyltrans-
ferase from T. gondii”
6th – 8th January 2010 University of Nottingham
CCP4 Study Weekend: “From Crystal to Structure with CCP4”
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